Document:

EX-10.4

 Exhibit 10.4 

 

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN
EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED 

This document is an English translation of a document prepared in German. In preparing this document, an attempt has been made to translate
as literally as possible without jeopardizing the overall continuity of the text. Inevitably, however, differences may occur in translation and if they do, the German text will govern by law. 

In this translation, German legal concepts are expressed in English terms and not in their original German terms. The concepts concerned may
not be identical to concepts described by the English terms as such terms may be understood under the laws of other jurisdictions. 

Licence Agreement 
  

of 01 January 2015 (“Commencement Date”) 

between 
 TRON-Translationale Onkologie an der
Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH (Translational Oncology at the University Medical Clinic of the Johannes Gutenberg University) 

Freiligrathstraße 12, 55131 Mainz 
 hereinafter referred to
as “TRON” 
 and 
 Johannes
Gutenberg-Universität Mainz (Johannes Gutenberg University of Mainz) 
 Saarstr. 21, 55122 Mainz; 

hereinafter referred to as the “JOHANNES GUTENBERG UNIVERSITY” 

and 
 University Medical Clinic of the Johannes
Gutenberg University Mainz 
 Langenbeckstr. 1, 55131 Mainz 

hereinafter referred to as “UNIVERSITY MEDICAL CLINIC” 

TRON, JOHANNES GUTENBERG UNIVERSITY and the UNIVERSITY MEDICAL CLINIC 

hereinafter referred to collectively as the “University-affiliated Parties” 

and 
 GANYMED Pharmaceuticals AG 

An der Goldgrube 12 

D-55131 Mainz 

hereinafter referred to as “GANYMED” 

  
 1 

  

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

 and 

BIONTECH AG 
 An der Goldgrube 12 

D-55131 Mainz 

hereinafter referred to as “BIONTECH” 

  
 2 

  

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

 TABLE OF CONTENTS 
  

							
	 PREAMBLE
	  	 	4	 
			
	 1.
	 	DEFINITION OF TERMS	  	 	4	 
			
	 2.
	 	LICENSED PATENTS	  	 	9	 
			
	 3.
	 	LICENCES	  	 	13	 
			
	 4.
	 	EXERCISE AND REPORTING OBLIGATIONS; MATERIAL TRANSFER	  	 	14	 
			
	 5.
	 	LICENSING FEES, TERMS AND CONDITIONS OF PAYMENT	  	 	15	 
			
	 6.
	 	WARRANTY, LIABILITY	  	 	18	 
			
	 7.
	 	EXEMPTIONS	  	 	19	 
			
	 8.
	 	CONFIDENTIALITY, PUBLICATIONS	  	 	20	 
			
	 9.
	 	TERM OF THE CONTRACT, TERMINATION	  	 	22	 
			
	 10.
	 	LEGAL CONSEQUENCES OF A TERMINATION	  	 	22	 
			
	 11.
	 	FINAL PROVISIONS	  	 	23	 

 APPENDICES 
  

			
	 Appendix 1.4
	  	BioNTech exclusive patents
	 Appendix 1.7
	  	BioNTech reagents
	 Appendix 1.8
	  	BioNTech other patents
	 Appendix 1.15
	  	Ganymed patents
	 Appendix 1.16
	  	Ganymed-University cooperation agreements
	 Appendix 1.18
	  	Community patents
	 Appendix 1.30
	  	Contract targets
	 Appendix 5.1
	  	Contract patents for use by GANYMED
	 Appendix 5.2
	  	Contract patents for use by BIONTECH
	 Appendix 5.4
	  	[***] contract patents

  
 3 

  

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

 PREAMBLE 
  

	A.	 GANYMED is a company that deals mainly with research and development of antibodies to fight cancer.

  

	B.	 BioNTech and the other companies in the BionTech Group are companies that are involved in the research and
development of other pharmaceutical solutions, including vaccines and cell therapies to fight cancer and other diseases. Overlaps between the activities of GANYMED and the BionTech Group are conceivable. 

 

	C.	 TRON is a company founded by the JOHANNES GUTENBERG UNIVERSITY, the UNIVERSITY MEDICAL CLINIC, Professor
Dr. Ugur Sahin and the State of Rhineland Palatinate, which conducts research and development in the fields of ecology and immunology with the aim of taking university research and development results and implementing them as part of practical
applications. 

  

	D.	 GANYMED, BIONTECH and the JOHANNES GUTENBERG UNIVERSITY have worked together for many years and together
achieved development results, most recently on the basis of the old cooperation agreement (as defined below). After the entry into force of the old cooperation agreement in March 2009, the other companies in the BionTech Group were founded as
BIONTECH subsidiaries, which have since each worked together with GANYMED and the JOHANNES GUTENBERG UNIVERSITY and together they have achieved development results. 

 

	E.	 The JOHANNES GUTENBERG UNIVERSITY, the UNIVERSITY MEDICAL CLINIC and TRON have reached different agreements
with each other since the conclusion of the old cooperation agreement which, among other things, relate to the transfer of rights and duties arising from the old cooperation agreement as well as the transfer of patents and know-how for which GANYMED and/or BIONTECH have been granted licences. 

  

	F.	 The Parties shall end with the old cooperation agreement upon conclusion of this license agreement. Taking the
place of the old cooperation agreement, from the time of commencement of (i) this license agreement, which modifies the licences between the parties to the industrial patents and the know-how and which
existed prior to the conclusion of this licence agreement, as well as in (ii) separate research and development contracts, which GANYMED, and one or more companies in the BionTech Group independently conclude with TRON and, if necessary, the
UNIVERSITY MEDICAL CLINIC in relation to the further cooperation. 

  

	1.	 DEFINITIONS OF TERMS 

For the purposes of this contract, the following terms have the meaning stated below: 

1.0 “Working day” means any day which is not a Saturday, Sunday or a public holiday in the domicile of a party. 

1.1 “Old cooperation agreement” is the cooperation, purchase and licensing agreement dated 30 December 2008 between the JOHANNES GUTENBERG
UNIVERSITY, GANYMED, and BIONTECH, including the supplementary agreement of 24 August 2009. 

  
 4 

  

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

 1.2 “BioNTech area of application” includes all areas of application of contractual products
outside of the Ganymed area of application. [***]. 
 1.3 “BioNTech development results” are all inventions, the entire know-how, technologies and other knowledge in the BionTech Group, which constituted BioNTech development results within the meaning of the old cooperation agreement and/or which can be the subject of rights of use
granted to GANYMED by the BionTech Group at the time of commencement, and which were achieved on the basis of cooperation between one or more companies in the BionTech Group and the JOHANNES GUTENBERG UNIVERSITY and the UNIVERSITY MEDICAL CLINIC
and/or TRON in connection with the old cooperation agreement before the time of commencement. The other BioNTech patents, BioNTech exclusive patents and Community patents are not development results. 

1.4 “BioNTech exclusive patents” are the patents and patent applications filed and scheduled as listed in Appendix 1.4, as well as
patent applications registered by 31.12.2015 and encompass BioNTech development results. For the purposes of clarification: BioNTech exclusive patents are covered by the licence pursuant to Section 3.1. 

1.5 The “BioNTech Group” is BIONTECH, BioNTech RNA Pharmaceuticals GmbH (formerly: “Ribological”), BioNTech Cell & Gene
Therapies GmbH (formerly: “UniCell”), BioNTech Diagnostics GmbH (formerly: “Theracode”), BioNTech Protein Therapeutics GmbH (formerly: “Tulip”) and JPT Peptide Technologies GmbH. With the exception of JPT Peptide
Technologies GmbH, the registered office of all companies in the BioNTech Group listed in the commercial register at the time of entry into force of this contract: An der Goldgrube 12, 55131 Mainz, Germany. The registered office of JPT Peptide
Technologies GmbH listed in the commercial register at the time of entry into force of this contract is: Volmerstraße 5, 12489 Berlin, Germany. 
 1.6
“BioNTech patents” are other BioNTech patents and BioNTech exclusive patents, but not Community patents. For the purposes of clarification: If a BioNTech patent is transferred to GANYMED, it is no longer a BioNTech patent, but
rather a Ganymed patent. 
 1.7 “BioNTech reagents” are (i) the reagents referred to in Appendix 1.7 and the know-how that is required for the use of reagents, and (ii) additional reagents added in accordance with Section 3.5, as well as the know-how required for the use of
these reagents, insofar as the BioNTech and/or the University-affiliated Parties can grant rights of use to these reagents and the necessary know-how at the time of entry into force. 

1.8 “Other BioNTech patents” are the patents and patent applications filed and scheduled as listed in Appendix 1.8, as well as patent
applications registered by 31.12.2015 and encompass BioNTech development results. For the purposes of clarification: Other BioNTech patents are not covered by the licence pursuant to Section 3.1. 

1.9 “BioNTech contract products” are all products developed, manufactured and/or marketed by BIONTECH, its affiliated companies, legal
successors, and/or licensees (or sublicensees). For the purposes of this definition, GANYMED and BIONTECH are not classified as affiliated companies, legal successors, licensees or sublicensees. 

  
 5 

  

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

 1.10 “Change of Control” is the date on which the majority shareholding relationships at
GANYMED change from the state at the time of commencement in such a way that a new shareholder of GANYMED can exert a dominant influence on GANYMED; a change of control, however, is not present if a financial investor (and not a strategic investor
or competitor) acquires shares in GANYMED. 
 1.11 “Third parties” are all natural and legal persons with the exception of TRON, the
JOHANNES GUTENBERG UNIVERSITY, the UNIVERSITY MEDICAL CLINIC, GANYMED, BIONTECH and all affiliated companies of the Parties. 
 1.12 “Development
results” are Ganymed results of development and BioNTech development results. 
 1.13 “Ganymed area of application” is the
research, development, validation, production, approval and exploitation of the contract products listed below and related to the contract Targets: 
  

	i.	 antibodies, antibody fragments and antibody fusion proteins within the meaning of recombinant proteins, which
bind to one or more contract targets [***] (“Ganymed Anti-bodies”). By contrast, this shall not include non-immunoglobulin-based binding proteins (such as micro-proteins) and Ganymed
Antibodies, not administered as a polypeptide, but e.g. as RNA. [***]; 

  

	ii.	 [***]; 

  

	iii.	 [***]; 

  

	iv.	 [***]; and 

  

	v.	 [***]; 

as well as [***]. 
 1.14 “Ganymed development
results” are all inventions, the entire know-how, technologies and other knowledge of GANYMED, which constituted GANYMED development results within the meaning of the old cooperation agreement and/or
which can be the subject of rights of use granted to GANYMED by the BionTech Group at the time of commencement, and which were achieved between GANYMED and the JOHANNES GUTENBERG UNIVERSITY and the UNIVERSITY MEDICAL CLINIC and/or TRON in connection
with the old cooperation agreement before the time of commencement in connection with (i) the old cooperation agreement and/or (ii) on the basis of the Ganymed-University cooperation agreements. Ganymed patents are not Ganymed development
results. 
 1.15 “Ganymed patents” are (i) the patents listed in Appendix 1.15, as well as (ii) patents registered during
the term of this agreement and encompass Ganymed development results. For the purposes of clarification: Ganymed patents are covered by the licence pursuant to Section 3.2. Community patents are not Ganymed patents. For the purposes of further
clarification: If a Ganymed patent is transferred to a company in the BionTech Group, it is no longer a Ganymed patent, but rather becomes a BioNTech patent. 

  
 6 

  

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

 1.16 “Ganymed-University cooperation agreements” are the contracts listed in Appendix
1.16 between GANYMED and the JOHANNES GUTENBERG UNIVERSITY, which preceded the old cooperation agreement. 
 1.17 “Ganymed contract
products” are all products developed, manufactured and/or marketed by GANYMED, its affiliated companies, legal successors, and/or licensees (or sublicensees). For the purposes of this definition, GANYMED and BIONTECH are not classified as
affiliated companies, legal successors, licensees or sublicensees. 
 1.18 “Community patents” are (i) the patents listed in
Appendix 1.18 and (ii) patents, registered during the term of this agreement, and encompass Ganymed development results and BioNTech development results. 

1.19 “Valid claim” if a claim that is granted, and has not lapsed or been legally declared null and void due to the expiry of the property
right or the withdrawal of the respective patent. In the case of pending patent applications, there is a valid claim for a term of seven (7) years from the date of priority of the respective patent if no previous application for examination has
been made, but no longer than for a term of ten (10) years from the date of priority of the respective patent. 
 1.20 “Net sales
price” is the amount charged to a third party for the purchase of a contract product from GANYMED and/or BIONTECH, its affiliated companies, legal successors or licensees or sublicensees, for which GANYMED and/or BIONTECH claims a licence
based on this agreement, minus the following items, if such deductions were actually granted or are attributable to the contract product according to the applicable generally accepted accounting principles: 

 

	 	i.	 Value added taxes, duties and fees for the manufacture, import or use of the contract products;

  

	 	ii.	 Standard quantity discounts and cash discounts; 

 

	 	iii.	 Credits for returned contract products or for deferred discounts; and 

 

	 	iv.	 Costs of transport and transport insurance if these costs are part of the sales price of the contract products
and listed as a separate item in the respective invoice. 

 The net sales price for each contract product is charged only once, namely
upon the first sale of the contract product in question by GANYMED and/or BIONTECH, its affiliated companies or sublicensees to a third party which is neither an affiliated company nor a sub-licensee of the
respective party. 
 1.21 The “Parties” are BIONTECH, GANYMED, TRON, the JOHANNES GUTENBERG UNIVERSITY and the UNIVERSITY MEDICAL
DEPARTMENT and a “Party” is GANYMED, BIONTECH, TRON, the JOHANNES GUTENBERG UNIVERSITY or the UNIVERSITY MEDICAL CLINIC. For the purposes of this licence agreement, TRON, JOHANNES GUTENBERG UNIVERSITY and the UNIVERSITY MEDICAL CLINIC act
jointly as the “University-affiliated Parties”. “University-affiliated Parties” is used as a simplified collective term for the three full parties; in the respective context in accordance with this agreement, these are obliged
and entitled jointly and/or individually and for themselves. A common authorisation or obligation on the part of the TRON, the JOHANNES GUTENBERG UNIVERSITY and the UNIVERSITY MEDICAL CLINIC in the sense of a total debt, total creditor liability,
community of joint owners or joint venture is therefore not intended. 

  
 7 

  

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

 1.22 “Patents” are all (i) patents, patent applications, utility models, including
subsequent applications, divisions, partial applications, extensions, additional patents, supplementary protection certificates and corresponding protections applied for or issued in individual countries or worldwide, as well as (ii) all
patents, patent applications, including subsequent applications, divisions, partial applications, extensions, additional patents, supplementary protection certificates and corresponding protections which claim the priority of a patent under (i).

 1.23 “Targets” [***]. 
 1.24
“Sublicensee” is each licensee who obtains a license to the contractual patents not from the right holder from but a licensee or sublicensee of the right holder. Sublicensee also includes
sub-sublicensees, etc. “Sublicences” have a corresponding meaning. 
 1.25 “Affiliated
companies” in relation to each Party are all companies, (i) in which a Party directly or indirectly holds more than fifty percent (50%) of the voting shares or in any other way, for example contractually, via special voting rights or
voting agreements, is entitled to exercise a decisive influence on is management, (ii) which directly or indirectly hold more than fifty percent (50%) of the voting shares in a Party or are otherwise entitled to exercise a dominant influence
over the management of the Party, or (iii) if more than fifty percent (50%) of the voting shares held or a dominant influence is exercised on the management by a person or a company who holds more than fifty percent (50%) of the voting shares
of this Party will or exerts a dominant Influence on the management of this Party. Within the meaning of this contract, (a) Athos Service GmbH, with its registered office at Rosenheimer Platz 6, 81669 Munich and (b) Santo (Deutschland)
Holding GmbH, with its registered office at Tölzer Strasse 12, 83607 Holzkirchen, (c) AT Impf GmbH, with its registered office at Rosenheimer Platz 6, 81669 Munich, (d) ATS Beteiligungsverwaltung GmbH, with its registered office at
Rosenheimer Platz 6, 81669 Munich and (e) companies exercising influence in accordance with paragraph (i)—(ii), if this influence is exerted over the three companies listed above, are not classified as affiliated companies. 

1.26 “Contract” is this license agreement between the University-affiliated Parties, GANYMED, and BIONTECH, including its appendices. 

1.27 The “Contract territory” is all countries and territories worldwide. 

1.28 “Contract patents” are the BioNTech patents, Ganymed patents and Community patents. 

1.29 “Contract products” are the Ganymed contract products and BioNTech contract products. 

1.30 “Contract targets” are the targets listed in Appendix 1.30. 

1.31 “Confidential information” is all data and information, study results, documents, materials and knowledge, business and trade secrets of
the Parties, of which the Parties or their affiliated companies become aware of as part of the execution of this contract, the old cooperation 

  
 8 

  

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

 
agreement or the Ganymed-University cooperation agreements or will become aware of or which they have published or will publish. Confidential information of the Parties or their affiliated
companies also include the contents of this contract and the Ganymed-University cooperation agreements, as well as their respective development results. 

ADDITIONAL DEFINITIONS 
  

			
	BioNTech exempt party	  	Section 7.3
	Ganymed exempt party	  	Section 7.1
	Ganymed contract patent	  	Section 2.7
	Non-infringing parties	  	Section 9.3
	Legal successor	  	Section 11.5
	Party indemnified by the University-affiliated Parties	  	Section 7.5
	University-affiliated Parties	  	Title, Section 1.21
	Infringing party	  	Section 9.3
	Time of commencement	  	Title

  

	2.	 LICENSED PATENTS 

2.1 If an application has not yet been made, GANYMED is entitled to apply for a patent for the Ganymed development results in the name of GANYMED and TRON, to
maintain them and defend and enforce them with respect to third parties, and BioNTech is entitled to apply for a patent for the BioNTech development results on behalf of the respective participating companies in the BionTech Group and TRON to
maintain them, defend them and enforce them with respect to third parties. [***] and companies in the BionTech Group named as the applicant and TRON are entitled to BioNTech development results and BioNTech patents in equal parts to the extent that
the TRON is a co-owner. GANYMED, BIONTECH and TRON [***]. GANYMED, and BIONTECH shall agree who takes the lead in application, maintenance and defence of Community patents, depending on the importance of the
patent for the Ganymed area of application or the BioNTech area of application. GANYMED and/or BIONTECH shall inform the co-owners of the application and maintenance of contract patents and take suggestions
made by the parties concerning the application and maintenance into account accordingly. The costs of the application, tracking, maintenance, defence and enforcement of the contract patents shall be borne by GANYMED in the case of Ganymed patents,
and by BIONTECH in the case of BioNTech patents. The costs of the application, tracking, maintenance and defence shall be borne by [***] in the case of Community patents. 

2.2 The JOHANN GUTENBERG UNIVERSITY and/or THE UNIVERSITY MEDICAL CLINIC have transferred their joint ownership rights as well as their other rights and
obligations in relation to the contract patents, with the exception of the contract patents marked with a cross in a separate column in Appendix 1.15, with the agreement of 21 June 2011 to TRON and TRON has accepted the transfers. The transfers
have come into effect no later than at the time of entry into force of this contract. The JOHANNES GUTENBERG UNIVERSITY and the UNIVERSITY MEDICAL CLINIC hereby acknowledge that 

  
 9 

  

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

 
their rights and obligations to this contract patents were transferred effectively to TRON. BIONTECH and GANYMED hereby consent to the transfer of the joint ownership rights as well as the other
rights and obligations of the JOHANNES GUTENBERG UNIVERSITY and/or the UNIVERSITY MEDICAL CLINIC in relation to these contract patents to TRON. Appendix 1.15 labels a contract patent in which the JOHANNES GUTENBERG UNIVERSITY is the owner. The
Parties to this contract are entitled to exercise their rights and/or their share of the contract patents and development results to another Party to this contract, to affiliated companies or third parties. If another Party is a co-owner of the patent and/or development result to be transferred, the co-owner is to be informed of the transfer and the name of the new joint owner in writing prior to the
transfer. In this case, the transfer is only effective after such notification. The Party transferring their share of a contract patent and/or development result to a third party may, to the extent of this Party has been granted a licence under this
contract, grant the third party a sublicence to the share of the contract patent not transferred. In this case, the transferring party shall oblige the purchaser in accordance with the provisions of this contract, however, it remains obliged to
continue to fulfil its obligations under this contract. Alternatively, the transferring Party may transfer its license to the share of the contract patent not transferred to the purchaser with the effect of discharging the debt; this does, however,
require the approval of the co-owner. The consent shall not be unreasonably denied and shall be deemed granted if has not been refused with good reason and in writing within thirty (30) working days from
the date of receipt of the request for consent. Consent is not necessary insofar as the purchaser of the joint ownership share is a Party to this contract, or if the transfer of the contract patents is in connection with a transfer of contract in
accordance with Section 11.5. transfers in accordance with this Section 2.2. Transfers prior to the conclusion of this contract are hereby approved. 

2.3 [***]. 
 2.4 GANYMED is entitled to the exclusive right to
enforcement of Ganymed patents, BioNTech exclusive patents and Community patents against infringement of property rights in the Ganymed area of application, for which GANYMED bears the costs. BIONTECH is entitled to the exclusive right to
enforcement of Ganymed patents, BioNTech exclusive patents and Community patents against infringement of property rights in the BioNTech area of application and other BioNTech patents against infringement of property rights in the Ganymed area of
application and in the BioNTech area of application, for which BIONTECH bears the costs. If GANYMED, its affiliated companies, licensees and sub-licensees are not interested in the enforcement in accordance
with this Section 2.4, GANYMED shall offer BIONTECH the right to enforce, and if BIONTECH, its affiliated companies, licensees and sub-licensees are not interested in the enforcement in accordance with
this Section 2.4 and GANYMED is either the co-owner of the violated patent or owner of an exclusive license to the violated patent based on this contract, BIONTECH shall offer GANYMED the right to
enforce. Insofar as TRON is a co-owner of the above-mentioned patents, TRON is to be informed in writing about the offer to enforce in relation to the infringement of property rights to GANYMED and/or
BIONTECH. TRON may undertake the enforcement of the patent if BIONTECH or GANYMED do not exercise their respective preferential right within ten (10) working days after receipt of the notice in writing to TRON and GANYMED and/or BIONTECH. The
Parties shall, on request and at the expense of the Party entitled to enforce the respective rights, provide support in an appropriate way in connection with an action against an infringing party. 

  
 10 

  

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

 2.5 The Parties are obliged to issue and/or take all the necessary information, statements by witnesses,
statements and/or actions in all legal proceedings concerning the contract patents and to instruct the workers involved in the inventions accordingly.    The Parties shall issue the necessary statements and powers of attorney to
conduct the proceedings. The reasonable costs incurred here shall be borne by the Party who enforces the rights pursuant to Section 2.4; in all other cases involving Ganymed Patents, GANYMED shall bear the costs; for BioNTech patents, BIONTECH
shall bear the costs; for Community patents, [***] shall bear the costs [***]. 
 2.6 Revenue of [***] BIONTECH, [***] affiliates, licensees or sublicensees
resulting from the enforcement of these rights, including but not limited to revenue from damages, compensation, acknowledgement or a settlement, after deduction of all costs necessary for the enforcement incurred by [***] BIONTECH, including
lawyers’ fees, consulting and court costs, shall be treated as “other remuneration ” of [***] BIONTECH, [***] affiliates or sublicensees within the meaning of Sections [***] and 5.2 (b). 

2.7 If GANYMED, an affiliated company, licensee or sublicensee intends to give up a Ganymed patent or their share in a Community patent (“Ganymed
contract patent”) during the patent term, GANYMED shall inform TRON and BIONTECH of which in writing, if possible, four (4) months prior to the expiration of the deadlines relevant for patent protection. The same applies if GANYMED is
not interested in an application for a Ganymed contract patent in individual countries or if the non-application of a possible partial application is equivalent to giving up the patent. In this case, BIONTECH
has the right to demand the transfer of GANYMED’s share in the Ganymed contract patent to BIONTECH and to maintain the respective Ganymed contract patent at its own expense and to defend it and/or to file the respective county-specific
application or a partial application, and TRON may maintain the respective Ganymed contract patent at its own expense and defend it and/or file the respective country-specific application or a partial application if BIONTECH does not exercise its
preferential right within ten (10) working days after receipt of the notice in writing with respect to TRON and GANYMED. On request and at the expense of the BIONTECH and/or TRON, GANMYED shall take all steps that are necessary to allow
BIONTECH and/or TRON to conduct the application, maintenance and defence of the Ganymed contract patent and the transfer of their share of the Ganymed contract patent. The party who demands the transfer of the respective Ganymed contract patent to
it or submits the respective partial application shall grant Ganymed an irrevocable, perpetual, free and sublicensable license within the contract territory and in the Ganymed area of application, unless otherwise agreed between the respective
Parties. The license is exclusive insofar as the Ganymed contract patent or the partial application encompasses a contract target and it is non-exclusive in all other cases. The receiving Party shall indemnify
GANYMED from all inventor remuneration which GANYMED is obliged to pay on the basis of statutory provisions in relation to a Ganymed contract patent or a partial application transferred on the basis of this Section 2.7. The periods agreed in
this Section 2.7 shall begin to run at the earliest with the time of commencement, unless GANYMED has previously communicated to BIONTECH and TRON its 

  
 11 

  

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

 
intention to give up the patent prior to the time of commencement. In this case, the deadline for written information about the intention to give up the patent shall be, if possible, sixty
(60) days, and the deadline for a non-intended application shall be thirty (30) days prior to the expiration of the deadlines relevant for the patent protection. For the purposes of clarification:
Section 2.7 does not cover the sale and transfer of Ganymed contract patents on the basis of a separate purchase and transfer agreement, but GANYMED shall agree obligations in accordance with this Section 2.7 with any purchaser. 

2.8 Section 2.7 shall apply mutatis mutandis if BIONTECH, an affiliated company, a licensee or Sublicensee is not interested in filing an application for
a BioNTech exclusive patent in individual countries or do not file a possible partial application for a BioNTech exclusive patent or wish to give up a BioNTech exclusive patent or their share of a Community patent. The submission of such
country-specific applications or of partial applications is regulated according to Section 2.7. In this case, GANYMED and/or TRON (if GANYMED does not exercise its preferential right within ten (10) working days) has the right to transfer
BIONTECH’s share of the BioNTech patent or Community patent to GANYMED and/or TRON and GANYMED and/or the TRON shall grant BIONTECH an irrevocable, perpetual, free, non-exclusive and sublicensable licence
within the contract territory and in the BioNTech area of application under the respective patent. For the purposes of clarification: Section 2.8 does not cover the sale and transfer of BioNTech contract patents on the basis of a separate
purchase and transfer agreement, but BIONTECH shall agree obligations in accordance with this Section 2.8 with any purchaser. 
 2.9 In the case that a
contract patent or a share in a contract patent is given up, the payment obligations of the other Parties in accordance with Section 5 with respect to the transferring Party shall lapse for this contract patent. The same applies in the case of
the transfer of a contract patent to a Party for the payment obligations of the receiving Party with respect to the transferring Party concerning the respective contract patent. 

2.10 BIONTECH is obliged to make all reasonable efforts to apply for a patent for BioNTech development results by 31.12.2015, i.e. to file an application
giving rise to a right of priority. If BIONTECH is not interested in applying for a BioNTech patent, then BIONTECH shall be responsible for the obligations to offer referred to in Section 2.8. BIONTECH shall provide GANYMED and the
University-affiliated Parties on a regular basis, but at least once per calendar quarter, with detailed information about the current status regarding (i) the patent applications listed in Appendix 1.4 and 1.8, as well as (ii) the
preparation of the filing of the patent applications listed in Appendices 1.4 and 1.8 and/or planned such patent applications that have been filed in the meantime, and coordinate the next steps with GANYMED and the University-affiliated Parties. The
Parties shall mutually determine in a timely manner whether the above information is provided by BIONTECH in writing, by email or in any other way. 

  
 12 

  

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

	3.	 LICENCES 

3.1 GANYMED hereby receives, during the term of this agreement, for the research, development, validation, production, approval and the exploitation of Ganymed
contract products in the contract territory, irrevocably and for an indefinite period and in accordance with the provisions and limitations of this contract: 

(i) [***]; 
 (ii) [***]; and 

(iii) from BIONTECH in the Ganymed area of application, 
  

	 	•	 	 an exclusive right to the share of the Community patents, the BioNTech exclusive patents and the BioNTech
development results to which the respective company in the BionTech Group is entitled, insofar as these were brought to the attention of GANYMED before the time of commencement of this agreement by one of the companies in the BionTech Group or one
of the University-affiliated Parties. 

 3.2 BIONTECH hereby receives, during the term of this agreement, for the research, development,
validation, production, approval and the exploitation of BioNTech contract products in the contract territory, irrevocably and for an indefinite period and in accordance with the provisions and limitations of this contract: 

(i) from the University-affiliated Parties in the BioNTech area of application and in the Ganymed area of application, 

 

	 	•	 	 an exclusive right to the share of the other BioNTech patents and BioNTech reagents to which the
University-affiliated Parties are entitled; and 

  

	 	•	 	 an exclusive right to the share of the BioNTech development results to which the University-affiliated Parties
are entitled, which are not the subject of the licence in accordance with Section 3.1, and to the BioNTech patents that encompass these BioNTech development results; 

(ii) from the University-affiliated Parties in the BioNTech area of application, 
  

	 	•	 	 an exclusive right to the share of the Community patents, BioNTech exclusive patents, Ganymed patents and Ganymed
development results to which the University-affiliated Parties are entitled, insofar as these were brought to the attention of one of the companies in the BionTech Group or one of the University-affiliated Parties by GANYMED before the commencement
of this contract; and 

 (iii) from GANYMED in the BioNTech area of application 

 

	 	•	 	 an exclusive right to the share of the Community patents, Ganymed patents and Ganymed development results to
which the University-affiliated Parties are entitled, insofar as these were brought to the attention of one of the companies in the BionTech Group or one of the University-affiliated Parties by GANYMED before the commencement of this contract.

  
 13 

  

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

 3.3 For the purposes of clarification, insofar as this relates to licences from University-affiliated
Parties, the licence shall be issued by the University-affiliated Party who is the owner or co-owner of the respective development results or contract patent. The licences referred to in this Section 3
continue the licences of the old cooperation agreement and modify the licences in accordance with the provisions of this contract. An interruption of the licenses is not intended with this agreement. 

3.4 GANYMED and BIONTECH are entitled to sublicence all the rights from the licences referred to in Sections 3.1 to 3.2 to affiliated companies, another party
to this contract and third parties without prior consent. For the purposes of clarification: insofar as GANYMED and BIONTECH are co-owners of a licensed right, they are entitled to grant licenses for their
share of the respective right. If licences and/or sub-licences have been granted in the past, these are hereby approved by the respective rights owners. The Parties are obliged, as a sublicensor, to grant the
sublicensee the rights of use from the licence only under such conditions that are in line with the terms of this contract. The sublicensee has to commit on its part to be bound by the terms of this contract accordingly. The respective licensee
shall inform the licensor about the conclusion of a sublicence agreement in writing. The sublicensees are entitled to issue further sublicences, for which the above provisions of this Section 3.4 shall apply mutatis mutandis. 

3.5 BIONTECH hereby grants GANYMED a non-exclusive, sub-licensable and
royalty-free licence (or sublicence) to the BioNTech reagents including the BioNTech patents, insofar as they encompass BioNTech reagents for (i) internal research and development purposes and (ii) research, development, manufacturing,
validation, authorisation and utilisation of Ganymed contract products in the Ganymed area of application and in the contract territory that is irrevocable and perpetual. [***]. 

Upon signature of this contract, GANYMED has a claim to the updating of the list of BioNTech reagents, but only in relation to such reagents that GANYMED has
already been made aware of before the entry into force of this agreement by one of the companies in the BionTech Group or one of the University-affiliated Parties. 

After a change of control, the licence in accordance with Section (i) above shall expire. 

3.6 The University-affiliated Parties may use the contract patents and the development results only for their internal research purposes. 

3.7 [***]. 
 3.8 The Parties shall sign all documents and issue
all declarations at the expense of the respective licensee and work together with the respective licensee insofar as this is necessary for the registration of licences in the patent offices of the various countries in the contract territory. 

 

	4.	 EXERCISE AND REPORTING OBLIGATIONS; MATERIAL TRANSFER 

4.1 [***] 

  
 14 

  

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

 4.2 BIONTECH is obliged with respect to the University-affiliated Parties to itself or with the help of its
sublicensees, to the best of their ability, to support the development, approval, manufacturing and marketing of BioNTech contract products in the BioNTech area of application and within the contract territory. 

4.3 [***]. 
 4.4 At the time of commencement, the Parties and/or
their affiliated companies are in possession of materials provided to them by one of the other Parties prior to the conclusion or during the term of the old cooperation agreement or the Ganymed-University cooperation agreements. The materials remain
the sole property of the Party who provided the materials and may not be used by the other Parties or affiliated companies that received the materials only in relation to the exercising of the rights and licences granted in this contract. Each Party
who has received the materials from another Party undertakes to provide the materials safely and protected from loss, damage, theft, misuse, and unauthorised access and stored in accordance with the applicable laws, regulations and guidelines. They
shall continue to make sure that their affiliated companies, licensees, and sublicensees use the materials in the same way. Upon written request from the Party who provided the materials, the other party shall provide information to the best of
their knowledge as to whether and for what purposes the materials can be used. 
  

	5.	 LICENSING FEES, TERMS AND CONDITIONS OF PAYMENT 

5.1 [***] 
 5.2 For the BioNTech contract products sold in the
BioNTech area of application by BIONTECH , its affiliated companies or licensees and/or sublicensees in the scope of protection of a valid claim of at least one contract patent cases referred to in Appendix 5.2, BIONTECH shall pay the
University-affiliated Parties (a) a royalty in the amount of 
  

	(X)	 [***] percent ([***]%) of the net sales price of the BioNTech contract products for annual net sales prices per
BioNTech contract product up to [***] ([***]) and 

  

	(Y)	 [***] percent ([***]%) of the net sales price of the BioNTech contract products insofar as the annual net sales
prices per BioNTech contract product exceeds [***] ([***]); 

 and (b) in the case of licensing to third parties, a participation in
the amount of [***] percent ([***]%) of all upfront payments, milestone payments and other payments which BIONTECH or its affiliated companies of their licensees receives for the issuing of licenses (with the exception of ongoing royalties, in which
no participation pursuant to (b) is to be paid). 
 For the purposes of clarification: The payment obligation pursuant to letter (b) above does
not apply if BIONTECH transfers its co-ownership of a contract patent to a third party in connection with a transfer of contract in accordance with Section 11.5 and, in this context, transfers the license
to the co-ownership share of the University-affiliated Parties; the payment obligation set forth in letter (b) 

  
 15 

  

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

 
above does, however, also exist in the case of such a transfer of contract in accordance with Section 11.5 to the extent that the contract transfer is in line with a licence agreement, as is
concluded, as is typical for the industry, between small-medium sized biotechnology companies and medium-sized/large pharmaceutical companies, in which the licensee is to make an upfront payment, milestone
payments and sales-based payments (royalties). An asset deal with an earn-out scheme, in which the last payments become due upon approval of the product, would not be in line with any licence agreement, since
licence agreements typically stipulate that a large part of the remuneration is to be paid via sales-based licensing fees. A transfer of the co-ownership share of a contract patent outside the variants
regulated in Section 11.5 to a third party requires the approval of the co-owner in accordance with Section 2.2 above. 

The above payment obligations of BIONTECH exist only if BIONTECH also receives royalty payments due for the respective rights from the respective licensee or
sublicensee (i.e. a suspension of the royalty payment obligation in the event of a failure of the licensee’s/sublicensee’s and/or no payment obligation if late payments cannot be obtained). The foregoing sentence shall not apply if the
licensee or sublicensee is an affiliate of BIONTECH. BIONTECH is obliged to endeavour to enforce claims for royalties with respect to licensees and sublicensees suitably and provide evidence of this. 

5.3 The participation of [***] percent ([***]%) in accordance with Section 5.1 (b) or Section 5.2 (b) is to be offset against the royalty in
accordance with Section [***] 5.2 (a) in the case of all upfront payments, but not in the case of milestone payments and other payments, which means that, for example, in accordance with paragraph (a) only the royalties that exceed the
participation of the University-affiliated Parties in the upfront payments that have already been made pursuant to paragraph (b) are to be paid. For example, [***]. 

For the purposes of clarification: royalties are only payable if they are made for issuing of licenses. No participation is payable on fees, which are proven
to be paid for the provision of services, for the delivery of materials, etc.. Where applicable, in the case of a full remuneration, the share paid for the licenses is to be determined and royalties are only to be paid for this share. 

For the purposes of clarification: if a [***] BioNTech contract product in the BioNTech area of application is in the scope of protection of several contract
patents, this shall remain at the royalties pursuant to [***] Section [***] 5 .2. 
 5.4 The remaining licences, in particular (i) licences to the
contract patents referred to in Appendix 5.4, (ii) licences to development results and (iii) reciprocal licences between [***]. Insofar as inventor fees in relation to a [***] license to a contract patent become due or contractually agreed
services known at the time of the entry into force of this contract with respect to other investors become due for payment, the licensee shall indemnify the owner of the respective contract patent from all statutory and contractual claims owed in
this regard. For the purposes of clarification: The regulation pursuant to Section 5.4 (iii) does not affect the basic payment claim on the part of the University-affiliated Parties to payments pursuant to Section[***] 5.2; the payment
obligations shall pass to the other party if they have acquired a licence. 

  
 16 

  

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

 5.5 If GANYMED and/or BIONTECH acquires the right to use a contract patent (by licence or transfer of a
contract patent) in the area of application of the other Party, the Party who provided the right of use within the area of application of the other Party must also make the payments to the University-affiliated Parties referred to in Section[***]
5.2 for the uses in the area of application of the other Party. For the purposes of clarification: [***] more than one royalty pursuant to [***] Section 5.2 is not due for any contract product. 

5.6 Royalties are to be paid for each country within the contract territory and for each contract product, as long as the contractual products in the
respective country fall under a valid claim of a licensed contract patent. 
 5.7 All payments of royalties must be made in euros plus the applicable value
added tax. If net sales prices are collected in foreign currencies, these net selling prices are to be converted into euros at the rates of exchange published by the European Central Bank at 15:00 on the last business day of the respective billing
period. 
 5.8 Royalties in accordance with Section 5 are to be paid on a [***]. 

5.9 As licensees, the Parties shall keep all books, records and data, which are necessary to determine the accuracy and completeness of the statements
according to the principles of proper accounting. The University-affiliated Parties are entitled, given reasonable notice to have these books, records, and data inspected by an independent auditor once a year during the general business hours of the
licensee. An auditor is independent if a Party or one of its affiliates does not regularly commission it. The University-affiliated Parties shall assume the costs of the auditor, unless the audit reveals that there is a difference of [***] percent
([***]%) or more between the bill of the respective licensee and that of the auditor at the expense of the University-affiliated Parties, in which case the costs shall be borne by the licensee in question. Differential amounts are immediately due
and payable. 
 5.10 In accordance with the old cooperation agreement, the JOHANNES GUTENBERG UNIVERSITY has transferred the ownership of the patents listed
in a separate column in Appendix 1.8 and marked with a cross to BIONTECH and BIONTECH paid the JOHANNES GUTENBERG UNIVERSITY a purchase price for this. As a BIONTECH obligation with respect to the JOHANNES GUTENBERG UNIVERSITY transferred from the
old cooperation agreement to this agreement, BIONTECH must make the following payments to the JOHANNES GUTENBERG UNIVERSITY: 
  

	i.	 a first milestone payment in the amount of [***] ([***]) if a clinical Phase Ilb trial or an equivalent
clinical phase of an authorisation procedure is started for a BioNTech contract product in the scope of protection of a valid claim of one of the other BioNTech patents marked in Appendix 1.8. The first milestone payment is due for the first
BioNTech contract product that meets the above condition; and 

  

	ii.	 a second milestone payment in the amount of [***] ([***]) if a clinical Phase Ilb trial or an equivalent
clinical phase of an authorisation procedure is completed for a BioNTech contract product in the scope of protection of a valid claim of one of the other BioNTech patents marked in Appendix 1.8. A Phase IIb clinical trial or an equivalent clinical
phase shall be deemed to have been completed when the principal of the trial sensor receives the final report from the competent authority. The second milestone payment is due for the first BioNTech contract product that meets the above condition;
and 

  
 17 

  

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

	iii.	 a third milestone payment in the amount of [***] ([***]) is due upon approval of the first BioNTech contract
product by the European Medicines Agency (EMA) that falls in the scope of protection of a valid claim of one of the other BioNTech patents marked in Appendix 1.8. The third milestone payment is due for the first BioNTech contract product that meets
the above condition. 

 BIONTECH shall inform the University-affiliated Parties of the beginning of the preparation for starting clinical
phases for a BioNTech contract product that falls in the scope of protection of a valid claim of one of the other BioNTech patents marked in Appendix 1.8, and thereafter report annually on the progress of the preparation or the starting of clinical
phases and the approval. If the product with which each milestone is reached is a BioNTech contract, for which a payment obligation in accordance with Section 5.2 exists (or would arise upon the start of sales), [***] of the payments owed under
in this Section 5.10, shall be offset against all payments due under Section 5.2 (and vice versa). This means: (i) Payments pursuant to Section 5.2 are only to be made if they exceed [***] of the total sum of all payments already
made pursuant to this Section 5.10 in total and (ii) payments pursuant to this Section 5.10 are only to be made if they exceed [***] of the sum of all payments already made in accordance with Section 5.2 in total (i.e. pursuant
to Section 5.10 (i), (ii) and (iii). In addition, the payment claims as defined in Section 5.10 shall lapse as soon as they become due once each. 

The effectiveness of the transfer that has already taken place in accordance with the old cooperation agreement does not depend on the performance of the
payments in accordance with Sections 5.10 (i), (ii) or (iii). 
  

	6.	 WARRANTY, LIABILITY 

6.1 Each Party guarantees that it has the right to conclude this contract and to fulfil its obligations under this contract, and that no circumstances are
known to it that could impair one Party in the performance of its obligations under this contract. For the purposes of clarification, BIONTECH also guarantees that it is entitled to grant licences to the BioNTech patents, even if another member of
the BionTech Group is the owner of the BioNTech patents. 
 6.2 BIONTECH and the University-affiliated Parties shall inform GANYMED of intellectual property
rights and copyrights of third parties that are known or become known to them, which could be violated through the use of the Ganymed patents and the Ganymed development results in the Ganymed area of application. The same shall apply to GANYMED and
the University-affiliated Parties with respect to the BIONTECH for the BioNTech patents in the BioNTech area of application. 
 6.3 [***] 

  
 18 

  

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

 6.4 The Parties shall be liable to one another only for intent and gross negligence. In the case of gross
negligence, the liability for indirect damages, consequential damages and lost profits shall be excluded. 
  

	7.	 EXEMPTIONS 

7.1 GANYMED is obliged to indemnify the respective university-affiliated party or BIONTECH (“Party indemnified by Ganymed”) from all claims of
third parties which are asserted because: 
  

	 	i.	 third-party product liability claims are asserted in connection with the Ganymed contract products sold by
GANYMED, its affiliated companies, licensees or sublicensees; 

  

	 	ii.	 the Ganymed contract products sold by GANYMED, its affiliates, licensees or sublicensees do not meet the
requirements of applicable law and/or applicable approvals; 

  

	 	iii.	 GANYMED violates an obligation or warranties under this contract, or 

 

	 	iv.	 GANYMED or one of its auxiliary agents acts negligently. GANYMED is obliged to indemnify pursuant to this
Section 7.1 only under the following conditions: (ii) The Party indemnified by Ganymed informs GANYMED immediately in writing of the asserted claims; (ii) GANYMED alone is entitled to undertake the defence and conclude a settlement
concerning the claim; and (iii) the Party indemnified by Ganymed supports GANYMED in the defence of the claim to the best of its abilities. 

7.2 [***] 
 7.3 BIONTECH undertakes to provide the respective
University-affiliated Party or GANYMED (“Party Indemnified by BioNTech”) from all claims of third parties which are asserted because: 
  

	 	i.	 third-party product liability claims are asserted in connection with the BioNTech contract products sold by
BIONTECH, its affiliated companies, licensees or sublicensees; 

  

	 	ii.	 the BioNTech contract products sold by BIONTECH, its affiliates, licensees or sublicensees do not meet the
requirements of applicable law and/or applicable approvals; 

  

	 	iii.	 BIONTECH violates an obligation or warranties under this contract, or 

 

	 	iv.	 BIONTECH or one of its auxiliary agents acts negligently. BIONTECH is obliged to indemnify pursuant to this
Section 7.3 only under the following conditions: (ii) The Party indemnified by BioNTech informs BIONTECH immediately in writing of the asserted claims; (ii) BIONTECH alone is entitled to undertake the defence and conclude a settlement
concerning the claim; and (iii) the Party indemnified by BioNTech supports BIONTECH in the defence of the claim to the best of its abilities. 

7.4 BIONTECH’s obligations under Section 7.3 do not apply in relation to violation of patents of third parties if the violation would not have
occurred if the Party indemnified by BioNTech (ii) would have 

  
 19 

  

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

 
used the BioNTech patents in accordance with the provisions of this contract, (ii) would not have processed or changed the BioNTech patents without the consent of BioNTech, or
(iii) would not have used the BioNTech patents in combination with other products. 
 7.5 Each University-affiliated Party is obliged to indemnify
GANYMED and/or BIONTECH (“Party Indemnified by the University-affiliated Parties”) from all claims of third parties which are asserted because: 
  

	 	i.	 the respective University-affiliated Party violates an obligation or guarantee under this contract, or

  

	 	ii.	 the respective University-affiliated Party acts negligently. 

The University-affiliated Parties are obliged to indemnify pursuant to this Section 7.3 only under the following conditions: (ii) The Party
indemnified by the University-affiliated Party informs the University-affiliated Party immediately in writing of the asserted claims; (ii) the University-affiliated Party alone is entitled to undertake the defence and conclude a settlement
concerning the claim; and (iii) the Party indemnified by the University-affiliated Party supports the University-affiliated Party in the defence of the claim to the best of its abilities. 

7.6 The indemnity obligations pursuant to this Section 7 shall continue to exist for a period of fifteen (15) years beyond the termination of this
agreement. 
  

	8.	 CONFIDENTIALITY, PUBLICATIONS 

8.1 The Parties are obliged to keep the confidential information that they or their affiliated companies have received or will receive directly or indirectly
from one of the other Parties or their affiliated companies secret from third parties, not to make it accessible to third parties and only to use it for the purposes of this contract. The receiving Party shall in particular not use the confidential
information for the filing of patents, unless they are not empowered to do so on the basis of the provisions of this contract. The Parties shall oblige their affiliates, licensees and sublicensees to maintain secrecy in respect of confidential
information in accordance with this Section 8. 
 8.2 The above obligations shall not apply to such confidential information, of which the Party
receiving the information can prove that it 
  

	 	i.	 was already publicly accessible at the time of release or became accessible to the general public thereafter
through no fault of their own, 

  

	 	ii.	 was in their possession at the time of communication already without a breach of statutory or contractual
obligations, 

  

	 	iii.	 was made available to it by a third party without an obligation to secrecy and
non-use, subject to the proviso that these third parties did not receive the information directly or indirectly from one of the other Parties or 

 

	 	iv.	 must be communicated on the basis of statutory provisions of authorities. 

  
 20 

  

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

 8.3 The Parties are obliged to provide the confidential information only to those employees, agents, advisor,
investors, potential investors, purchasers and potential purchasers, licensees and potential licensees, sublicensees and potential sublicensees, insofar as they need to receive the information for the purposes of this contract or for the purposes of
the examination of this contract for the respective investment knowledge or the conclusion of a licence agreement, and on which the same substantive confidentiality obligations have been imposed that the Parties have entered into (in the case of
employees within the framework of the legal possibilities, including for the period after the termination of the employment relationship). The receiving Party shall, upon request, inform the other Parties of the names of employees who receive
information without delay and shall further provide evidence of the conclusion of a confidentiality agreement with the respective employee upon request. After termination of the contract and upon request, the Parties are obliged to return all
confidential information and copies thereof to the other Party or to destroy it according to their instructions, with the exception of 
  

	 	i.	 legal obligations of the receiving Party to keep confidential information 

 

	 	ii.	 computer files created on a regular basis due to automatic system backup, which are to be stored securely by
the receiving party, and 

  

	 	iii.	 the legal archiving of a single copy of all confidential information in order to ensure compliance with this
Section 8. 

 8.4 The Parties shall make publications during the term of this contract and up to ten (10) years after its
completion, insofar as this may affect the interests of other Parties, especially if the planned publication contains development results, only with the consent of the parties concerned. The affected Parties are obliged to give their consent or
state their objection within four (4) weeks after transfer of the complete manuscript of the planned publication. If the affected party does not object to the publication within this period, the consent shall be deemed as given. The 4-week period begins to run, however, only from the date of receipt of the manuscript confirmed in writing by the responsible contact person at the party concerned or his representative. An objection to a
publication may be raised only given just cause. Just cause exists in particular if a Party is still intending to submit applications for industrial property rights for inventive contributions in the publication in time; eight (8) weeks after
transfer of the complete manuscript of the planned publication is agreed as the maximum period, by which a publication may be delayed for the purpose of the registration of property rights. In the event of an objection, however, the parties
concerned shall, in particular where statutory final examinations, doctoral theses or post-doctoral theses are affected by the work of the project, in any case, jointly seek to reach a compromise on the time and/or content of a premature
publication, taking into account their legal obligations and legitimate interests, and those of the affected examinees, doctoral students or post-doctoral students. 

8.5 The Parties are entitled to make the conclusion of this agreement public. 

8.6 The confidentiality obligation shall continue to exist for ten (10) years after termination of this contract. 

  
 21 

  

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

	9.	 TERM OF THE CONTRACT, TERMINATION 

9.1 The contract shall take effect at the above-mentioned time of commencement and shall continue for as long as BIONTECH and GANYMED are obliged to pay
royalties in accordance with Section 5 above.    If the obligation of BIONTECH or of GANYMED to pay royalties ends, the contract between GANYMED and the University-affiliated Parties and/or between BIONTECH and the
University-affiliated Parties shall continue to exist as long as GANYMED and/or BIONTECH is still obliged to pay royalties. After the expiry of this contract, the Parties remain irrevocably entitled to the free, permanent, global and non-exclusive use of the licensed rights, including the right to sublicense. 
 9.2 Each Party is entitled to terminate
the rights licensed to them in whole or in part with a period of notice of six (6) months at the end of a calendar month. With the termination of the licence, the obligations of that Party in accordance with the foregoing Sections 3, 4 and 5 in
this respect shall terminate. The other licenses, and in particular the licenses which the terminating Party has granted to the other Parties and the rights and obligations under this contract relating to the contract patents and the existing
licenses shall continue to apply. 
 9.3 If one of the Parties (“Infringing Party”) violates an essential contractual obligation or is in
default of one of its obligations under this contract, the other Parties (“Non-Infringing Parties”) shall inform the Infringing Party of the infringement or the delay in writing and require
that the breach of contract or default be remedied immediately. A significant breach of contract is also present if the licensee contests the property rights of the licensor. If the Infringing Party does not remedy the violation or the delay within
sixty (60) days after receipt of the written notice from the Non-Infringing Parties, the Non-Infringing Party concerned is entitled to terminate, in writing, the
licence issued to the Infringing Party in accordance with Section 3 with respect to the Infringing Party in whole or in part. The termination of a licence in accordance with this Section 9.3 does not affect the right of Non-Infringing Party to claim compensation from the Infringing Party for damages it suffers due to the premature termination of the contract due to the breach of contract or default and any other claims. In the case
of a notice of termination of this contract issued to the Infringing Party pursuant to this Section 9.3, the contract between the other two Parties shall continue. 

9.4 Any termination must be made in the written form. 
  

	10.	 LEGAL CONSEQUENCES OF A TERMINATION 

10.1 In the case of a notice of termination of a licence or this agreement, the licensor shall be entitled to all payments made by the licensee, and the
licensee is obliged to settle all payment claims incurred prior to the termination of the contract, which shall become due immediately upon termination. Licences, which the licensor has granted the licensee for contract patents or contract products
not affected by the termination, as well as licences granted to the licensor by the licensee, shall remain unaffected by the termination of a licence or this contract. 

  
 22 

  

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

 10.2 Upon termination of a licence – for whatever reason – all sublicences which the respective
licensee has granted pursuant to this contract and are issued by the respective licensee to the respective licensor shall remain effective. The licensor is not obliged to disclose the obligations and commitments under the licence agreement, if and
to the extent to which they do not match the duties and obligations of the licensor under this contract. 
 10.3 If a licence expires, the respective
licensee undertakes to immediately suspend the further development, manufacturing, marketing and sale of contract products on the basis of this contract. However, the respective licensee has the right to continue to market and sell the contract
products existing upon termination of contract for a period of six (6) months after termination of the contract; the licensee remains obliged to continue to pay the remuneration in accordance with Section 5. 

10.4 The termination of this contract in accordance with the provisions above shall not affect the right of the Parties to take legal remedies and assert
existing claims. 
 10.5 Sections 1, 2, 4.4, 5.6, 5.7, 5.9 (5.6, 5.7, 5.9 where royalties incurred prior to termination of the contract or net sales prices
are concerned), 5.10, 6.3, 6.4, 7 (in accordance with the provisions of Section 7.6), 8, 10, 11.3, 11.6, 11.7, 11.8, 11.9 and 11.11 shall continue to apply even after termination of this contract. 

 

	11.	 FINAL PROVISIONS 

11.1 If TRON or the UNIVERSITY MEDICAL CLINIC have achieved development results within the meaning of the old cooperation agreement during the term of the old
cooperation agreement in place of the JOHANNES GUTENBERG UNIVERSITY and/or have become the owner of contract patents in place of the JOHANNES GUTENBERG UNIVERSITY, the TRON and the UNIVERSITY MEDICAL CLINIC hereby enter into the rights and
obligations of the JOHANNES GUTENBERG UNIVERSITY from the old cooperation agreement and authorise the use of these patents during the period of the old cooperation agreement. If the assignment of the joint ownership of development results has not
yet been made, the JOHANNES GUTENBERG UNIVERSITY, the UNIVERSITY MEDICAL CLINIC and TRON shall agree the assignment of the joint ownership of development results in accordance with the respective inventor shares in good faith between one another and
communicate the agreed assignment to GANYMED, and/or BIONTECH no later than thirty (30) days after the date of receipt of the invention notice in writing. If this notification is not made in a timely manner, are GANYME and/or BIONTECH shall be
entitled to name TRON as co-owner in patent applications based on this invention. 
 11.2 upon request from GANYMED
and BIONTECH and in order to simplify the mutual obligations and communication under this contract, the JOHANNES GUTENBERG UNIVERSITY and the University Medical Clinic shall each appoint TRON as their agent for issuing and receiving communications.

  
 23 

  

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

 
Regardless of the following procedural descriptions for the task of issuing and receiving communications, the JOHANNES GUTENBERG UNIVERSITY and the UNIVERSITY MEDICAL CLINIC do not issue TRON a
power of attorney or other power of representation. Ganymed and BIONTECH may render their respective obligations under this contract with respect to the JOHANNES GUTENBERG UNIVERSITY and the University Medical Clinic to TRON with the effect of
fulfilling the obligation. [***]. TRON shall satisfy its obligations as an agent for issuing and receiving communications for the JOHANNES GUTENBERG UNIVERSITY and the UNIVERSITY MEDICAL CLINIC with the diligence it applies in our own affairs.
[***]. The JOHANNES GUTENBERG UNIVERSITY, the UNIVERSITY MEDICAL CLINIC and TRON may cancel or alter the appointment by written information to all other Parties and appoint another University-affiliated Party accordingly. [***]. 

11.3 All events or circumstances, which the Parties do not have the power to prevent, in particular all cases of force majeure, shall release the parties from
performance of their contractual obligations for the duration of the disturbance and to the extent of its impact on the Parties. 
 11.4 This contract shall
enter into force in place of the old cooperation agreement and the Ganymed-University cooperation agreements and thus replaces, among other things, the provisions that are intended to continue to apply after the termination of the agreements. For
the remainder, this contract contains all agreements between the Parties on the subject of the contract and, from the time of commencement, shall replace all prior oral and written agreements between the Parties. For the purposes of clarification,
the provisions of this contract shall apply to all contract patents, regardless of under which pre-existing contract they were produced. 

11.5 The Parties are entitled to transfer their rights and obligations under this contract in whole or in part to (i) their affiliated companies,
(ii) any other party, and (iii) third parties, who acquire significant assets of the respective Party or their affiliated companies concerning this contract (“legal successors”). For the purposes of clarification, variant
(iii) of the preceding sentence also covers the sale of individual development programs, technologies, projects or products, insofar as the relevant patent or patents and the associated data and know-how
are transferred to the legal successor (e.g. by transfer of the relevant employees or other knowledge transfer). Such development programs, technologies, projects and products are considered to be “significant assets” for the purposes of
this Section 11.5. In contrast, the isolated transfer of a patent without the associated data and know-how does not constitute the transfer of “significant assets” for the purposes of this
Section 11.5. It is a prerequisite for the transfer to affiliated companies, another Party and legal successors that the affiliated company, another Party or the legal successor enters into the rights and obligations of the transferring party
under this contract in writing and confirms this in writing to the Parties. 
 11.6 All communications between the Parties concerning this contract shall be
sent by mail or by fax and a confirmation copy by post to the following addresses of the Parties: 
 To the university representative for the
University-affiliated Parties: 
 TRON-Translationale Onkologie an der Universitätsmedizin 

der Johannes Gutenberg Universität Mainz gemeinnützige GmbH Freiligrathstraße 12 

55131 Mainz 

  
 24 

  

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

 FAO Management 

To GANYMED: 
 Ganymed Pharmaceuticals AG 

An der Goldgrube 12 
 55131 Mainz

 FAO Management 
 To BIONTECH: 

BioNTech AG 
 An der Goldgrube 12

 55131 Mainz 
 FAO Management

 11.7 This contract is subject to German law. 
 11.8 With
respect to all disputes arising out of or in connection with this contract, mediation proceedings shall be carried out in accordance with the arbitration rules of the German Institution for Arbitration (DIS) as amended at the time of the
proceedings. The place of arbitration is Frankfurt. The number of arbitrators is one (1). The language for the mediation proceedings is German. If the dispute has not been settled in accordance with the mediation proceedings within sixty
(60) days after the request for mediation proceedings or within another period, on which the Parties agree, each party shall be entitled to lead the dispute to a decision in accordance with Section 11.9. 

11.9 After unsuccessful mediation proceedings in accordance with Section 11.8, any Party may turn to the ordinary courts of justice. The exclusive place
of jurisdiction for all disputes arising in connection with the contract or its validity is Mainz. To maintain confidentiality, all parties seek to the keep these matters in camera. No party shall oppose a request to keep the matters in camera. 

11.10 Each party warrants that the contract is concluded independently of sales transactions and procurement decisions and that there are no such expectations
in this regard. 
 11.11 Should individual provisions of this contract be or become effective, the validity of the remaining provisions remains unaffected
by this. The Parties are obliged to immediately replace an invalid or unenforceable provision with a valid or enforceable provision, which comes closest to the economic purpose of the provision to be replaced. The same applies to any regulatory
gaps. 
 11.12 Additions and changes to this contract require the written form and the signature of all the Parties, insofar as they relate to all Parties.
This also applies to a waiver of the requirement of the written form. If an addition or amendment of this contract affects only individual Parties, this addition or amendment shall only require the written consent of the Parties concerned. For the

  
 25 

  

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

 
purposes of clarification: GANYMED can, for example, without the consent of BIONTECH, agree on a different royalty with the University-affiliated Parties and GANYMED and BIONTECH can agree a
change in the respective areas of application without the consent of the University-affiliated Parties. The Party who is not affected by the amendment of the contract shall be informed about the contract amendment in writing. 

11.13 The appendices to this contract describe the state at the time of entry into force. The respective lists of the contract patents may change after the
time of entry into force, for example, if other patents are filed, which encompass development results, or contract patents may be transferred from GANYMED to BIONTECH or BIONTECH to GANYMED. The Parties shall update the appendices on a regular
basis and make the up-to-date appendices available to the Parties. The updating of the appendices is not constitutive and does not constitute a change of the contract.

  
 26 

  

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

 Ganymed Pharmaceuticals AG 
  

							
	Place, date	  	Mainz, 13.03.2015	  		  	Mainz, 16.03.2015
	Signed by:	  	[***]	  	Signed by:	  	[***]
	Name:	  	[***]	  	Name:	  	[***]
	Function:	  	[***]	  	Function:	  	[***]

 BioNTech AG 
  

							
	Place, date	  	Mainz, 16.03.2015	  		  	Mainz, 16.03.2015
	Signed by:	  	[***]	  	Signed by:	  	[***]
	Name:	  	[***]	  	Name:	  	[***]
	Function:	  	[***]	  	Function:	  	[***]

 Johannes Gutenberg University, Mainz 
  

							
	Place, date	  	Mainz, 16.03.2015	  		  	
	Signed by:	  	[***]	  	Signed by:	  	                        
	Name:	  	[***]	  	Name:	  	
	Function:	  	[***]	  	Function:	  	

  
 27 

  

			
	Confidential! 	  	 Ganymed Pharmaceuticals AG
 JGU, TRON,
BioNTech, University Medical Clinic – Licence Agreement
 Execution copy

 

 TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
gemeinnützige GmbH (Translational Oncology at the University Medical Clinic of the Johannes Gutenberg University) 
  

							
	Place, date	  	Mainz, 16.03.2015	  		  	
	Signed by:	  	[***]	  	Signed by:	  	[***]
	Name:	  	[***]	  	Name:	  	[***]
	Function:	  	[***]	  	Function:	  	[***]

 University Medical Clinic of the Johannes Gutenberg University, Mainz 

 

							
	Place, date	  	Mainz, 14.04.2015	  		  	
	Signed by:	  	[***]	  	Signed by:	  	[***]
	Name:	  	[***]	  	Name:	  	[***]
	Function:	  	[***]	  	Function:	  	[***]
				
	Place, date	  	10.04.2015	  		  	
	Signed by:	  	[***]	  		  	
	Name:	  	[***]	  		  	
	Function:	  	[***]	  		  	

  
 28 

 Appendix 1.4: BioNTech exclusive patents 

 

															
	 File ref.
	  	 Original
applicant
	  	 Owner
	  	 Title or “Catch Title”
	  	 Date of
application,
application
giving rise
to a
right of
priority
	  	 Subsequent or initial
application
No.
(Publication No.)*
	  	 Target (if
the
subject
of
the
invention)
	  	 Designation
pursuant
to
Appendix
1.15

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

 [***] 

  
 29 

 Appendix 1.7: BIONTECH reagents 

A) Project [***] 
  

							
	 Reagent No.
	  	 Reagent designation
	  	 Reagent
type
	  	 Description

	1	  	[***]	  	[***]	  	[***]
	2	  	[***]	  	[***]	  	[***]
	3	  	[***]	  	[***]	  	[***]
	4	  	[***]	  	[***]	  	[***]
	5	  	[***]	  	[***]	  	[***]
	6	  	[***]	  	[***]	  	[***]
	7	  	[***]	  	[***]	  	[***]
	8	  	[***]	  	[***]	  	[***]
	9	  	[***]	  	[***]	  	[***]
	10	  	[***]	  	[***]	  	[***]
	11	  	[***]	  	[***]	  	[***]
	12	  	[***]	  	[***]	  	[***]
	13	  	[***]	  	[***]	  	[***]
	14	  	[***]	  	[***]	  	[***]
	15	  	[***]	  	[***]	  	[***]

 B) Project [***] 
  

							
	 Reagent No.
	  	 Reagent designation
	  	 Reagent
type
	  	 Description

	17	  	[***]	  	[***]	  	[***]
	18	  	[***]	  	[***]	  	[***]
	19	  	[***]	  	[***]	  	[***]
	20	  	[***]	  	[***]	  	[***]
	21	  	[***]	  	[***]	  	[***]
	22	  	[***]	  	[***]	  	[***]
	23	  	[***]	  	[***]	  	[***]
	24	  	[***]	  	[***]	  	[***]
	25	  	[***]	  	[***]	  	[***]
	26	  	[***]	  	[***]	  	[***]
	27	  	[***]	  	[***]	  	[***]
	28	  	[***]	  	[***]	  	[***]
	29	  	[***]	  	[***]	  	[***]
	30	  	[***]	  	[***]	  	[***]
	31	  	[***]	  	[***]	  	[***]
	32	  	[***]	  	[***]	  	[***]
	33	  	[***]	  	[***]	  	[***]
	34	  	[***]	  	[***]	  	[***]
	35	  	[***]	  	[***]	  	[***]
	36	  	[***]	  	[***]	  	[***]
	37	  	[***]	  	[***]	  	[***]
	38	  	[***]	  	[***]	  	[***]
	39	  	[***]	  	[***]	  	[***]
	40	  	[***]	  	[***]	  	[***]

  
 30 

							
	 Reagent No.
	  	 Reagent designation
	  	 Reagent
type
	  	 Description

	41	  	[***]	  	[***]	  	[***]
	42	  	[***]	  	[***]	  	[***]
	43	  	[***]	  	[***]	  	[***]
	44	  	[***]	  	[***]	  	[***]
	45	  	[***]	  	[***]	  	[***]
	46	  	[***]	  	[***]	  	[***]
	47	  	[***]	  	[***]	  	[***]
	48	  	[***]	  	[***]	  	[***]
	49	  	[***]	  	[***]	  	[***]

 C) Projects [***] and [***] 
  

							
	 Reagent No.
	  	 Reagent designation
	  	 Reagent type
	  	 Description

	50	  	[***]	  	[***]	  	[***]
	51	  	[***]	  	[***]	  	[***]
	52	  	[***]	  	[***]	  	[***]
	53	  	[***]	  	[***]	  	[***]
	54	  	[***]	  	[***]	  	[***]
	55	  	[***]	  	[***]	  	[***]
	56	  	[***]	  	[***]	  	[***]
	57	  	[***]	  	[***]	  	[***]
	58	  	[***]	  	[***]	  	[***]
	59	  	[***]	  	[***]	  	[***]
	60	  	[***]	  	[***]	  	[***]
	61	  	[***]	  	[***]	  	[***]
	62	  	[***]	  	[***]	  	[***]
	63	  	[***]	  	[***]	  	[***]
	64	  	[***]	  	[***]	  	[***]
	65	  	[***]	  	[***]	  	[***]
	66	  	[***]	  	[***]	  	[***]
	67	  	[***]	  	[***]	  	[***]
	68	  	[***]	  	[***]	  	[***]
	69	  	[***]	  	[***]	  	[***]
	70	  	[***]	  	[***]	  	[***]
	71	  	[***]	  	[***]	  	[***]
	72	  	[***]	  	[***]	  	[***]

 D) Other reagents 
  

							
	 Reagent No.
	  	 Reagent designation
	  	 Reagent type
	  	 Description

	16	  	[***]	  	[***]	  	[***]
	73	  	[***]	  	[***]	  	[***]
	74	  	[***]	  	[***]	  	[***]
	75	  	[***]	  	[***]	  	[***]

  
 31 

 Appendix 1.8: Other BIONTECH patents 

 

													
	 File ref.
	  	 Original

applicant
	  	 Owner
	  	 Title
	  	 Date of

application,
application

giving rise to a
 right of
priority
	  	 Subsequent or initial
application No.
(Publication
No.)
	  	 Designation

pursuant to
 Section 5
..10

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

 [***] 

  
 32 

 Sub-appendix to 1.4 and 1.8: Tron-BionTech joint projects

  

													
	 Project number
	  	
Project name / description
	  	 Content of the project
	  	 Status
	  	 Patent family
	  	
Title and content of the
submitted / planned
application

	 TRON
	  	 BionTech

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]
	  	 [***]

	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

 Sub-appendix to 1.4 and 1.8: Tron-BionTech joint projects 

 

													
	 Project number
	  	
Project name / description
	  	 Content of the project
	  	 Status
	  	 Patent family
	  	
Title and content of the
submitted / planned
application

	 TRON
	  	 BionTech

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]
	  	 [***]

  
 33 

													
	 Project number
	  	
Project name / description
	  	 Content of the project
	  	 Status
	  	 Patent family
	  	
Title and content of the
submitted / planned
application

	 TRON
	  	 BionTech

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]
	  	 [***]

  
 34 

 Sub-appendix to 1.4 and 1.8: Tron-BionTech joint projects

  

													
	 Project number
	  	
Project name / description
	  	 Content of the project
	  	 Status
	  	 Patent family
	  	
Title and content of the
submitted / planned
application

	 TRON
	  	 BionTech

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

  
 35 

 Sub-appendix to 1.4 and 1.8: Tron-BionTech joint projects

  

													
	 Project number
	  	 Project name / description
	  	 Content of the project
	  	 Status
	  	 Patent family
	  	
Title and content of the
submitted / planned
application

	 TRON
	  	 BionTech

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

  
 36 

 Sub-appendix to 1.4 and 1.8: Tron-BionTech joint projects

  

													
	 Project number
	  	 Project name / description
	  	 Content of the project
	  	 Status
	  	 Patent family
	  	
Title and content of the
submitted / planned
application

	 TRON
	  	 BionTech

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

 Sub-appendix to 1.4 and 1.8: Tron-BionTech joint projects 

 

													
	 Project number
	  	 Project name / description
	  	 Content of the project
	  	 Status
	  	 Patent family
	  	
Title and content of the
submitted / planned
application

	 TRON
	  	 BionTech

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

  
 37 

													
	 Project number
	  	 Project name / description
	  	 Content of the project
	  	 Status
	  	 Patent family
	  	
Title and content of the
submitted / planned
application

	 TRON
	  	 BionTech

							
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

 Sub-appendix to 1.4 and 1.8: Tron-BionTech joint projects 

 

													
	 Project number
	  	 Project name / description
	  	 Content of the project
	  	 Status
	  	 Patent family
	  	
Title and content of the
submitted / planned
application

	 TRON
	  	 BionTech

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

  
 38 

 Appendix 1.15: Ganymed patents 

 

															
	 File ref.
	  	 Original
applicant
	  	 Owner
	  	 Designation acc.
to Section 2.2
	  	 “Catch Title”
	  	 Date of
application,
application
giving rise to
a
right of priority
	  	 Subsequent or
initial application
No.
(WO
Publication No.)*
	  	 Contract
targets, see
Appendix 1.30

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

 [***] 

  
 39 

 Appendix 1.16: Ganymed-University cooperation agreements 

[***] 

  
 40 

 Appendix 1.18: Community patents 

 

											
	 File ref.
	  	Original applicant	 	Owner	 	Title / [***]
“Catch Title”	 	Date of
application,
application
giving rise to a
right of
priority	 	Subsequent
or initial
application
No. (WO
Publication
No.)
	 [***]
	  	[***] **	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***] **	 	[***]	 	[***]	 	[***]	 	[***]

 [***] 

  
 41 

 Appendix 1.30: Contract targets 

File references and SEQ ID NOs are provide for orientation purposes only and are not conclusive. 

 

							
	 No.
	  	Name of the contract target
(alternative designation(s))	 	[***] file ref.	 	Protein SEQ ID NOs as per
file ref.
	 1
	  	[***]	 	[***]	 	[***]
	 2
	  	[***]	 	[***]	 	[***]
	 3
	  	[***]	 	[***]	 	[***]
	 4
	  	[***]	 	[***]	 	[***]
	 5
	  	[***]	 	[***]	 	[***]
	 6
	  	[***]	 	[***]	 	[***]
	 7
	  	[***]	 	[***]	 	[***]
	 8
	  	[***]	 	[***]	 	[***]
	 9
	  	[***]	 	[***]	 	[***]
	 10
	  	[***]	 	[***]	 	[***]
	 11
	  	[***]	 	[***]	 	[***]

  
 42 

 Appendix 5.1: Contract patents for use by [***] 

5.1 
  

							
	 [***] file ref.
	  	 Owner
	  	 “Catch title”
	  	 Subsequent or initial

application No. (WO

Publication No.)

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

  
 43 

 5.1 Continuation (BionTech exclusive patents) 

 

							
	 [***] file ref.
	  	 Owner
	  	 Title or [***] “Catch title”
	  	 Subsequent or initial

application No. (WO

Publication No.)*

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

				
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

 5.1 Continuation (Community patents) 
  

							
	 File ref.
	  	 Owner
	  	
Title or GANYMED “Catch title”
	  	 Subsequent or initial

application No. (WO

Publication No.)

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  		  		  	

  
 44 

 Appendix 5.2: Contract patents for use by BionTech 

 

							
	 [***] file ref.
	  	 Owner
	  	 “Catch title”
	  	 Subsequent or initial

application No. (WO

Publication No.)

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

  
 45 

 5.2 Continuation 
  

							
	 [***] file ref.
	  	 Owner
	  	 Title or “Catch title”
	  	 Subsequent or initial

application No. (WO

Publication No.)

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

				
	 [***]**
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]**
	  	 [***]
	  	 [***]
	  	 [***]

  
 46 

 5.2 Continuation (Community patents) 

 

							
	 File ref.
	  	 Owner
	  	
Title / GANYMED “Catch title”
	  	 Subsequent or initial

application No. (WO

Publication No.)

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  		  		  	

  
 47 

 Appendix 5.4 Free contract patents 

 

							
	 File ref.
	  	 Owner
	  	 “Catch title” or Title
	  	 Subsequent or initial

application No. (WO

Publication No.)

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  		  		  	

  
 48EX-10.5

 Exhibit 10.5 

THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH
(i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED 
 EXECUTION VERSION 

 
  

FRAMEWORK COLLABORATION AGREEMENT 
  

 
 between 

TRON Translationale Onkologie 
 an
der Universitätsmedizin 
 der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH 

Freiligrathstraße 12 
 D-55131 Mainz, Germany 
 hereinafter referred to as “TRON” 

and 
 BioNTech SE 

An der Goldgrube 12 
 D-55131 Mainz, Germany 
 hereinafter referred to as “BIONTECH” 

and the subsidiaries of BIONTECH: 

BioNTech RNA Pharmaceuticals GmbH 

An der Goldgrube 12 
 D-55131 Mainz, Germany 
 and 

BioNTech Diagnostics GmbH 
 An der
Goldgrube 12 
 D-55131 Mainz, Germany 

and 

 BioNTech Protein Therapeutics GmbH 

An der Goldgrube 12 
 D-55131 Mainz, Germany 
 and 

BioNTech Cell & Gene Therapies GmbH 

An der Goldgrube 12 
 D-55131 Mainz, Germany 
 and 

BioNTech Innovative Manufacturing Services GmbH 

Vollmersbach road 66 
 D-55743 Idar-Oberstein, Germany 
 and 

JPT Peptide Technologies GmbH 

Volmerstrasse 5 
 D-12489 Berlin, Germany 
 hereinafter jointly referred to as “BIONTECH SUBSIDIARIES” 

BIONTECH and the BIONTECH SUBSIDIARIES hereinafter jointly referred to as the “BIONTECH GROUP” 

Effective as of 
 1 January
2015 

  

			
	Strictly confidential	 	2

					
	Preamble    	  	 	4	 
		
	1.      Definitions	  	 	5	 
		
	2.      Fields of cooperation	  	 	10	 
		
	3.      Implementation of WP5 PROJECTS	  	 	11	 
		
	4.      Duties of the parties	  	 	13	 
		
	5.      Industrial property rights and copyrights, rights to results	  	 	14	 
		
	6.      Financial terms, terms of payment	  	 	17	 
		
	7.      Warranty, liability	  	 	22	 
		
	8.      Confidentiality, publications	  	 	23	 
		
	9.      Term, termination	  	 	25	 
		
	10.    Final clauses	  	 	26	 
		
	         Signature pages	  	 	29	 
		
	 Annex 1A and Annex 1B: List of current (as of the date of execution of this WP5 AGREEMENT) WP5 PROJECTS
covered by this WP5 AGREEMENT according to clause 2.2
	  	 	31	 
		
	 Annex 2: TEMPLATE agreement on a WP5 PROJECT
	  	 	34	 
		
	 Annex 3: TEMPLATE of a declaration for persons involved in WP5 PROJECTS who are not employed by TRON or by a
subcontractor involved in a relevant WP5 PROJECT (e.g. diploma students, Masters students, PhD students)
	  	 	39	 
		
	 Annex 4: List of Patent Applications (as of the date of execution of this WP5 AGREEMENT) which covers WP5
PROJECTS covered by this WP5 AGREEMENT
	  			

  

			
	Strictly confidential	 	3

 PREAMBLE 
  

	A.	 BIONTECH is a company which, together with the BIONTECH SUBSIDIARIES, is focused on the development of
innovative molecular immune therapies and biomarker-based diagnostic approaches for the individualised treatment of cancer and other serious diseases. 

  

	B.	 TRON is a company founded by the UNIVERSITY (as defined below), UNIMED (as defined below), Professor
Dr. Ugur Sahin and the State of Rhineland-Palatinate. TRON conducts research in the fields of translational oncology and immunology with the aim of implementing them for practical and/or clinical application. 

 

	C.	 TRON works closely with UNIMED. In collaboration with TRON, UNIMED also carries out work with or for TRON on a case-by-case basis, also in the framework of TRON co-operations with THIRD PARTIES (as defined below). 

 

	D.	 BIONTECH, the UNIVERSITY and Ganymed Pharmaceuticals GmbH have worked together for many years and achieved
joint development results, last based on the FORMER COOPERATION AGREEMENT (as defined below). Following the entry into force of the FORMER COOPERATION AGREEMENT, BioNTech RNA Pharmaceuticals GmbH, BioNTech Diagnostics GmbH, BioNTech Protein
Therapeutics GmbH and BioNTech Cell & Gene Therapies GmbH were founded in March 2009 as subsidiaries of BIONTECH and have also worked together with Ganymed Pharmaceuticals GmbH and the UNIVERSITY. The FORMER COOPERATION AGREEMENT has been
terminated under the LICENCE AGREEMENT (as defined below). 

  

	E.	 Subsequently, the BIONTECH GROUP and TRON have entered into the WP3 AGREEMENT (as defined below) and, in
addition, have concluded the [***] to regulate their continued cooperation. This WP5 AGREEMENT serves to provide the additional framework for the various collaborations of the PARTIES on a case-by-case basis. In contrast to the FORMER COOPERATION AGREEMENT, it is no longer the UNIVERSITY but TRON that is the contracting party of the BIONTECH GROUP. 

 

	F.	 The companies of the BIONTECH GROUP intend to collaborate regularly with

  

			
	Strictly confidential	 	4

	 	
TRON within the framework of various research and development projects. This WP5 AGREEMENT therefore regulates the terms and conditions for these collaboration projects, which TRON agrees to
carry out with one or more specific companies of the BIONTECH GROUP (such specific company of the BIONTECH GROUP in each case referred to as the “BIONTECH PARTY”). Within the framework of this collaboration, the PARTIES shall define the
respective work programmes for WP5 PROJECTS based on this WP5 AGREEMENT. 

  

	1.	 Definitions 

For the purposes of this WP5 AGREEMENT, the following terms shall have the following meanings: 

“AFFILIATE” means, with respect to a Person, any other Person that now or in the future, directly or indirectly through one or
more intermediaries, controls, is controlled by or is under common control with such Person, as applicable, but only for so long as such other Person continues to control, be controlled by, or be under common control with such first Person. As
used in the definition of “AFFILIATE”, “control” means (a) to possess, directly or indirectly, the power to direct the management or policies of a Person, whether through ownership of voting securities, by contract relating
to voting rights or corporate governance, or otherwise, or (b) direct or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular
jurisdiction) of the voting share capital or other equity interest in a Person.
 “BIONTECH PARTY” has the meaning given to
it in Recital F. 
 “CALENDAR YEAR” is a year that begins on January 1 and ends with the following December 31. 

“CONFIDENTIAL INFORMATION” is all data and information, study results, documents, materials and findings, business and trade
secrets of the PARTIES gathered by the PARTIES or disclosed to one another under this WP5 AGREEMENT. CONFIDENTIAL INFORMATION includes WP5 RESULTS and the content of this WP5 AGREEMENT, its annexes and any associated agreements, such as quality
agreements and WP5 PROJECT AGREEMENTS, 

  

			
	Strictly confidential	 	5

 
which shall be considered to be the CONFIDENTIAL INFORMATION of all PARTIES and with respect to which each PARTY shall be considered to be both a disclosing party and a receiving party. 

“CONTROL” means, with respect to any patents, know-how, materials, information or any
other intellectual property, the legal authority or right (whether by ownership, license or otherwise but without taking into account any rights granted by one PARTY to the other PARTY pursuant to this WP5 AGREEMENT) of a PARTY to grant access, a
license or a sublicense of or under such patents, know-how, materials, information or other intellectual property to the other PARTY, or to otherwise disclose proprietary or trade secret information to such
other PARTY, in each case, without breaching or violating the terms of any then-existing agreement with any THIRD PARTY, or misappropriating or otherwise violating such proprietary or trade secret information of any THIRD PARTY. 

“EFFECTIVE DATE” means 1 January 2015. 

“EXCESS CLAIM” has the meaning given to it in clause 5.3. 

“FIELD” shall mean (a) for the WP5 PROJECTS listed in Annex 1A (and other WP5 PROJECTS as mutually agreed by the
PARTIES) the prophylaxis, diagnosis and treatment of all indications in humans and animals (“FIELD I”), (b) for the WP5 PROJECTS listed in Annex 1B (and other WP5 PROJECTS as mutually agreed by the PARTIES) the
prophylaxis, diagnosis and treatment of oncological diseases, infectious diseases and rare genetic diseases (“FIELD II”), and (c) for the RNT PROJECT the prophylaxis, diagnosis and treatment of rectal neuroendocrine tumors in
humans (“RNT FIELD”). 
 “FORMER COOPERATION AGREEMENT” is the cooperation, transfer and licence
agreement dated 30 December 2008 between the UNIVERSITY, Ganymed Pharmaceuticals AG and BIONTECH, including its supplementary agreement dated 24 August 2009. 

[***]. 
 “LICENCE
AGREEMENT” is the licence agreement between BIONTECH, TRON, UNIMED, the UNIVERSITY and Ganymed Pharmaceuticals AG, dated 1 January 2015. 

  

			
	Strictly confidential	 	6

 “NET SALES PRICE” is the gross amount invoiced to a THIRD PARTY for the
sale of a WP5 CONTRACTUAL PRODUCT by a BIONTECH GROUP company or its licensees (or sublicensees), less the following deductions if and to the extent actually made and attributable to the WP5 CONTRACTUAL PRODUCT under generally accepted accounting
principles, consistently applied: 
 (i) any VAT payable on the sale of WP5 CONTRACTUAL PRODUCTS; any customs duties and other public charges
for the manufacture, import or use of WP5 CONTRACTUAL PRODUCTS; 
 (ii) customary quantity and cash discounts; 

(iii) credits for returned WP5 CONTRACTUAL PRODUCTS or for retroactive price reductions; 

(iv) costs of transport and transport insurance if and to the extent these costs are included in the sales price of the WP5 CONTRACTUAL
PRODUCTS and are shown separately on the respective invoice. 
 The NET SALES PRICE is calculated only once for each WP5 CONTRACTUAL PRODUCT,
namely upon the first sale of the relevant WP5 CONTRACTUAL PRODUCT by the relevant BIONTECH GROUP company or its licensees (or sublicensees) to a THIRD PARTY which is neither a licensee nor a sublicensee of the relevant PARTY. 

“PARTIES” are jointly the companies of the BIONTECH GROUP and TRON, and “PARTY” is individually BIONTECH,
BioNTech RNA Pharmaceuticals GmbH, BioNTech Diagnostics GmbH, BioNTech Cell & Gene Therapies GmbH, BioNTech Protein Therapeutics GmbH, Eufets GmbH and JPT Peptide Technologies GmbH and TRON. 

“PERSON” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership,
corporation, limited liability company, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political subdivision, department or agency of a government. 

“PRE-EXISTING KNOWLEDGE” is all industrial property rights, know-how, technologies and other knowledge of TRON, which may be useful for the implementation of a WP5 PROJECT and is CONTROLLED by TRON at the 

  

			
	Strictly confidential	 	7

 
EFFECTIVE DATE or at any point during the term of the respective WP5 Project but otherwise than as a result of the performance of a WP5 PROJECT. 

“RNT PROJECT” shall mean the research conducted by TRON prior to the execution of this WP5 AGREEMENT relating to the
characterization and validation of [***] as targets of an active ingredient for the treatment of rectal neuroendocrine tumors. 

“RNT PROJECT RESULTS” has the meaning given to it in clause 2.4. 

“TRADE SECRET INVENTION” is an invention (a) forming part of WP5 RESULTS, (b) which (i) TRON alone, or (ii) the
PARTIES jointly, achieve in the implementation of a WP5 PROJECT and within the framework of the respective agreed WP5 PROJECT objectives, (c) which is patentable, and (d) for which the PARTIES mutually agree to not to file an application
for WP5 PROJECT PATENTS. 
 “THIRD PARTIES” are all PERSONS that are not PARTIES nor AFFILIATES of either PARTY. 

“UNIMED” is the Universitätsmedizin der Johannes Gutenberg-Universität Mainz,
D-55099 Mainz, Germany. 
 “UNIVERSITY” is the Johannes Gutenberg-Universität
Mainz, D-55099 Mainz, Germany. 
 “VALID CLAIM” is a claim of a patent which has
been granted and has not expired or has not been declared null and void as a result of the expiry of the term of the property right or the withdrawal of the respective patent. In the case of pending patent applications, a VALID CLAIM exists for a
period of [***] years from the priority date of the respective application or until it is (in each case finally and unappeable) withdrawn, rejected or lapses, whichever is the earlier. 

“WP3 AGREEMENT” is the framework agreement for research services between the PARTIES of 1 January 2015, designed as Work
Package 3 of the structuring of the cooperation between TRON and the BIONTECH GROUP. 
 “WP5 AGREEMENT” is this framework
cooperation agreement between the 

  

			
	Strictly confidential	 	8

 
BIONTECH GROUP and TRON, including its facilities, designated as “Work Package 5” of the structuring of the partnership between TRON and the BIONTECH GROUP. 

“WP5 CONTRACTUAL PRODUCTS” are all products developed, manufactured and/or marketed by a BIONTECH GROUP company, and/or
licensees (or sublicensees) or their successors in title, which contain or make use of a WP5 RESULT and/or a RNT PROJECT RESULT and fall under a WP5 PROJECT PATENT and/or a TRADE SECRET INVENTION. 

“WP5 PROJECTS” are the respective working programmes and objectives to be defined by TRON and one or more of the BIONTECH
PARTIES pursuant to clause 2.1 of this WP5 AGREEMENT. WP5 PROJECTS may comprise, on the one hand, WP5 PROJECT WORK to be assigned to the field of innovative applied research and to be carried out as independently as possible by TRON, whereby the
individual work steps and objectives for the WP5 PROJECT PARTIES cannot yet be determined in detail upon agreement of the WP5 PROJECT, and on the other hand, determinable services in the area of research and development or in the area of clinical
research. 
 “WP5 PROJECT AGREEMENT” shall have the meaning given to it in clause 3.1. 

“WP5 PROJECT PARTIES” are TRON and the respective BIONTECH PARTY. 

“WP5 PROJECT PATENTS” are all patents, patent applications, divisional applications, supplementary protection certificates,
additional patents and utility models filed in individual countries or worldwide from [***] and which claim WP5 RESULTS and/or RNT PROJECT RESULTS. For clarification: a WP5 PROJECT PATENT only exists if TRON employees are inventors or co-inventors of the invention in question under German patent law. If the definition of the BioNTech Patent Rights of the LICENCE AGREEMENT also applies to a WP5 PROJECT PATENT at the same time, only the LICENCE
AGREEMENT, and not this WP5 AGREEMENT, shall apply to such WP5 PROJECT PATENT. For clarification: If patent applications have been filed under the LICENCE AGREEMENT on or before [***] in accordance with regulations 1.4, 1.8 and 2.10 of the LICENSE
AGREEMENT, these patents or 

  

			
	Strictly confidential	 	9

 
patent applications shall be subject only to the LICENCE AGREEMENT, irrespective of whether WP5 PROJECT WORK or WP5 RESULTS have also been provided in this WP5 AGREEMENT by [***]. 

“WP5 PROJECT WORK” is research activities undertaken within the scope of a WP5 PROJECT to achieve WP5 RESULTS. 

“WP5 RESULTS” are all inventions, methods, specifications, materials, documents, data,
know-how and other results (if covered by the specification of the work programme for the respective WP5 PROJECT and whether or not patentable) which (i) TRON alone, or (ii) the respective PARTIES
jointly achieve in carrying out activities of a WP5 PROJECT and within the framework of the respective agreed WP5 PROJECT objectives. 
  

	2.	 Areas of cooperation 

 

	2.1	 The cooperation between the PARTIES is envisaged in the areas and with the contents and objectives as agreed in
each of the WP5 PROJECTS. 

  

	2.2	 Currently, the PARTIES are already collaborating in the projects listed in Annexes 1A and 1B
which are deemed WP5 PROJECTS. 

  

	2.3	 In the event TRON owns or otherwise CONTROLS any intellectual property or other results, including results from
any other projects or activities other than WP5 PROJECTS, and, at its sole discretion, determines to offer a license to such results to BIONTECH, the PARTIES shall in good faith discuss and negotiate whether and, if so, at what terms and conditions
(including adequate financial terms) such license may be granted. 

  

	2.4	 Since BIONTECH has expressed its interest in acquiring a right to exploit the results generated and CONTROLLED
by TRON in the conduct of the RNT PROJECT (the “RNT PROJECT RESULTS”), TRON agrees to license such project results to BIONTECH as if they are WP5 RESULTS pursuant to what is specifically set forth in this WP AGREEMENT with respect
to the RNT PROJECT RESULTS in further detail. 

  

			
	Strictly confidential	 	10

	3.	 Implementation of WP5 PROJECTS 

 

	3.1	 The WP5 PROJECT WORK to be conducted for each WP5 PROJECT shall be agreed between the relevant BIONTECH PARTY
and TRON by concluding a written description of the respective WP5 PROJECT (“WP5 PROJECT AGREEMENT”) before the project starts. AFFILIATED COMPANIES of BIONTECH which are added in writing by mutual agreement after conclusion of the
WP5 AGREEMENT are also entitled to agree WP5 PROJECTS with TRON on the basis of this WP5 AGREEMENT. 

 In each WP5 PROJECT
AGREEMENT, TRON and the BIONTECH PARTY shall agree at least the following: 
  

	 	•	 	 the designation of the FIELD as either FIELD I or FIELD II, 

 

	 	•	 	 tasks, scope and objectives of the WP5 PROJECT WORK to be provided by TRON, 

 

	 	•	 	 the start and anticipated end date for WP5 PROJECT WORK, 

 

	 	•	 	 the budget, 

  

	 	•	 	 the project reporting requirements (content and frequency), 

 

	 	•	 	 the participation and/or contribution of the BIONTECH PARTY, if required, and if the BIONTECH PARTY is to
participate, the extent of its participation. 

 For the purpose of agreeing a WP5 PROJECT AGREEMENT, TRON shall, as a
rule, propose to the BIONTECH PARTY that wishes to make use of TRON’s WP5 PROJECT WORK within the framework of a WP5 PROJECT, upon request of the BIONTECH PARTY, a WP5 PROJECT AGREEMENT which shall address the points set out above. 

The template description of a WP5 PROJECT and WP5 PROJECT AGREEMENT is attached as Annex 2. To the extent that the terms of a WP5
PROJECT AGREEMENT conflicts with the provisions of this WP5 AGREEMENT, the provisions of this WP5 AGREEMENT shall prevail unless the individual WP5 PROJECT AGREEMENT clearly states otherwise with express reference to the WP5 AGREEMENT. 

Each and every WP5 PROJECT AGREEMENT shall incorporate and be read in conjunction with the terms of the body of this WP5 Agreement and together
constitute the entire agreement between TRON and the relevant BIONTECH PARTY for that WP5 PROJECT, but each WP5 PROJECT AGREEMENT shall be a unique agreement and shall stand alone with respect to any other WP5 PROJECT AGREEMENT. 

  

			
	Strictly confidential	 	11

	3.2	 This WP5 AGREEMENT shall not give rise to a claim by TRON or the companies of the BIONTECH GROUP for the
agreement or execution of certain projects or for the provision of a certain scope of services or work. In particular, it shall not give rise to any obligation on the part of TRON to maintain certain personnel or technical capacities.

  

	3.3	 The WP5 PROJECT PARTIES shall provide each other with all information necessary for carrying out the WP5
PROJECT WORK. Any documents and materials made available by one PARTY to the other PARTY for that purpose shall be made available without transferring title thereto and shall be subject to the confidentiality obligation in clause 8. They shall be
used exclusively for the purposes of this WP5 AGREEMENT or WP5 PROJECTS and shall be returned to the respective PARTY at the end of the relevant WP5 PROJECT. 

  

	3.4	 TRON is entitled, with the written consent of the BIONTECH PARTY, to subcontract THIRD PARTIES to provide
individual WP5 PROJECT WORK. The consent of the companies of the BIONTECH GROUP is deemed granted for TRON subcontracting UNIMED and the UNIVERSITY. In each subcontracting agreement with a THIRD PARTY, TRON shall ensure that the THIRD PARTY
subcontractor is obliged to provide the subcontracted WP5 SERVICES in accordance with provisions not less stringent than the applicable provisions of this WP5 AGREEMENT and the relevant WP5 PROJECT AGREEMENT, and shall be responsible for the
compliance by any such THIRD PARTY with the applicable provisions of the WP5 AGREEMENT and the relevant WP5 PROJECT AGREEMENT. The appointment of a THIRD PARTY shall not negate or affect TRON’s duties and responsibility to the relevant BIONTECH
PARTY to perform the subcontracted WP5 SERVICES. In particular, TRON shall enter into non-disclosure agreements with THIRD PARTIES in accordance with clause 8 prior to the disclosure of information and
materials. 

  

	3.5	 The BIONTECH PARTY shall be entitled to propose changes to the content and/or timing of the WP5 PROJECTS that
it has agreed with TRON. TRON shall also draw the attention of the BIONTECH PARTY to any changes to WP5 PROJECTS that TRON believes are necessary or useful. Changes to WP5 PROJECTS shall be made after agreement between the PARTIES by means of

  

			
	Strictly confidential	 	12

	 	
a written amendment agreement. TRON shall support the BIONTECH PARTY to the best of its ability in preparing a change request and shall provide all the necessary information as promptly as
possible. The amendment of a WP5 PROJECT shall take effect as soon as the PARTIES have signed the amendment agreement. 

  

	4.	 Duties of the Parties 

 

	4.1	 TRON shall perform the WP5 PROJECT WORK in compliance with scientific standards, all relevant technical
laboratory and legal regulations and with the due care and attention customary in the non-clinical biotechnology research industry. It shall allocate the necessary resource and required qualified personnel to
complete the WP5 PROJECT WORK on time. TRON shall properly document and store the content and results of the work it performs, including raw data. 

  

	4.2	 BIONTECH shall provide TRON with any equipment that TRON does not have and which is required for the execution
of the WP5 PROJECTS, following agreement and, in so far as is reasonable, free of charge. The WP5 PROJECT PARTIES shall inform each other, through their project managers, of all processes, problems, innovations and technical and scientific knowledge
relating to the WP5 PROJECTS. 

  

	4.3	 TRON and the BIONTECH PARTY shall regularly inform each other in detail about the status of the WP5 PROJECT
WORK and TRON shall regularly inform the BIONTECH PARTY of the achieved WP5 RESULTS, and, if necessary, shall provide copies of the research documents for the evaluation of the WP5 RESULTS. Should the WP5 PROJECT PARTIES determine that the objective
of a WP5 PROJECT cannot be achieved or cannot be achieved as planned, they shall inform each other immediately. 

  

	4.4	 Upon request, unless otherwise agreed, TRON shall provide the BIONTECH PARTY with a final report for a specific
WP5 PROJECT which shall reflect TRON’s WP5 RESULTS and other findings relevant to the WP5 PROJECT and include the resulting relevant documents, manufacturing instructions and research documentation, including electronic data.

  

			
	Strictly confidential	 	13

	4.5	 TRON and the BIONTECH PARTY shall keep each other informed of the progress of their assigned work under the
respective WP5 PROJECT AGREEMENT, and to the extent permitted by applicable law BIONTECH shall keep TRON reasonably informed of the further development of WP5 CONTRACTUAL PRODUCTS (pre-clinical and clinical
trials, filings of applications to authorities, approvals, collaborations or licensing) through the contacts of both PARTIES named in the respective WP5 PROJECT AGREEMENT. 

 

	4.6	 The BIONTECH PARTY shall use its reasonable efforts to develop and commercialise WP5 CONTRACTUAL PRODUCTS,
either itself or by granting sublicences, by exploiting the WP5 RESULTS to the extent it has the rights of use under clause 5.1 of this WP5 AGREEMENT. 

  

	5.	 Industrial property rights and copyrights, rights to results 

 

	5.1	 If one of the WP5 PROJECT PARTIES obtains patentable WP5 RESULTS within the framework of WP5 PROJECTS, it shall
notify the respective other WP5 PROJECT PARTY without undue delay in writing by means of a corresponding invention disclosure. Patentable WP5 RESULTS, documentation relating thereto and materials produced within the framework of a WP5 PROJECT are
jointly owned by TRON and the BIONTECH PARTY, and the RNT PROJECT RESULTS, including patentable RNT PROJECT RESULTS, shall be solely owned by TRON. Subject to the provisions of clauses 5.5 and 5.6, TRON hereby grants the respective BIONTECH PARTY an
exclusive, worldwide, sublicensable license under its interest in the WP5 RESULTS and the RNT PROJECT RESULTS to research and have researched, develop and have developed, make and have made, use, and otherwise commercialize or have commercialized,
and otherwise commercially exploit, WP5 CONTRACTUAL PRODUCTS in the respective FIELD. 

 If the BIONTECH PARTY intends to
grant sublicences, it shall keep TRON informed of the progress of such negotiations with the prospective sublicensee to the extent permitted by applicable laws and subject to TRON giving reasonable undertakings with respect to such disclosure,
including with respect to not using such information for insider trading. The BIONTECH PARTY shall provide TRON with a copy of the agreements with sublicensees. 

  

			
	Strictly confidential	 	14

 For the avoidance of doubt, as for the RNT PROJECT RESULTS, TRON shall have the exclusive
right to (i) research and have researched, RNT PROJECT RESULTS outside the RNT FIELD and (ii) research and have researched, develop and have developed, make and have made, use, and otherwise commercialize or have commercialized, and
otherwise commercially exploit RNT PROJECT RESULTS outside the RNT FIELD if and to the extent the RNT PROJECT(S) can be used for more than one indication that would reasonably have no commercial effect on the commercialisation of RNT PROJECT RESULTS
inside the RNT FIELD. 
  

	5.2	 The BIONTECH PARTY shall be responsible for filing, maintaining, defending and enforcing patentable WP5 RESULTS
against THIRD PARTIES and agreeing with TRON on the appropriate procedure, and shall regularly, but at least every [***] months, report on the current status to TRON. TRON shall use reasonable efforts to assist the BIONTECH PARTY in all matters
relating to the ownership of the WP5 RESULTS and the filing, prosecution and maintenance of patent applications covering the WP5 RESULTS. 

Should the BIONTECH PARTY not wish to maintain an industrial property right or a published application for an industrial property right, it
shall first offer the relevant right to TRON for a free takeover. In the case of a RNT PROJECT RESULT, for which TRON does not wish to maintain an industrial property right or a published application for an industrial property right, TRON shall
notify the BIONTECH PARTY thereof in due course in writing to allow the BIONTECH PARTY the reasonably required time to take over the respective proceeding and appropriately continue the application or registration, as applicable. Should a BIONTECH
PARTY elect not to file a patent application claiming an invention forming part of WP5 RESULTS but instead maintain it as a TRADE SECRET INVENTION, the BIONTECH PARTY shall confirm its decision to TRON in writing latest [***] business days from the
BIONTECH PARTY’s receipt of TRON’s information about the respective invention. 
  

	5.3	 Each of the PARTIES undertakes not to publish WP5 RESULTS eligible for intellectual property rights without the
prior written consent of the other PARTY. TRON will require its subcontractors, in particular UNIMED, to do so to the extent legally possible and to ensure that TRON becomes the owner of the WP5 RESULTS that the subcontractors (in particular UNIMED)
obtain. The compensation under employee invention law (Arbeitnehmererfindergesetz) for 

  

			
	Strictly confidential	 	15

	 	
the WP5 PROJECT PATENT or TRADE SECRET INVENTION of the employees of TRON or its subcontractors is incumbent upon TRON or its subcontractors, provided, however that, if and to the extent the TRON
employee has, other than as a result of an agreement between TRON and the employee concluded without the approval of the respective BIONTECH PARTY, a claim against TRON for compensation under German employee invention law for any WP5 RESULTS which
exceeds the compensation calculated on the basis of the consideration received by TRON from the respective BIONTECH PARTY for such WP5 RESULT and such claim is not based on an allegation of negligence or wilful misconduct on the part of TRON (an
“EXCESS CLAIM”), the BIONTECH PARTY shall indemnify TRON for such EXCESS CLAIM, it being understood that (i) TRON shall not, without the prior written consent of the respective BIONTECH PARTY, grant any employee any such EXCESS CLAIM,
(ii) TRON shall not settle an EXCESS CLAIM without the prior written consent of the relevant BIONTECH PARTY, (iii) in the event that a TRON employee should bring a claim before the German Bundespatentgericht or otherwise sue TRON in any
court of competent jurisdiction for an EXCESS CLAIM, the BIONTECH PARTY shall have the right, but not the obligation, to control, with TRON’s reasonable support, the litigation, and (iv) the relevant BIONTECH PARTY shall have no obligation
to indemnify TRON against an EXCESS CLAIM until such claim has been upheld by a final, unappealable decision of a court of competent jurisdiction unless the relevant BIONTECH PARTY, in its sole discretion, agrees otherwise. 

 

	5.4	 TRON shall ensure that persons who are not employed by TRON or any of its subcontractors are not included in
WP5 PROJECTS until they have made a declaration in accordance with the template attached to this WP5 AGREEMENT as Annex 3. 

  

	5.5	 The right of the BIONTECH PARTY to use the WP5 RESULTS and the RNT PROJECT RESULTS in the respective FIELD as
provided in clause 5.1 is subject to the retained rights of TRON and its AFFILIATES to use all WP5 RESULTS and the RNT PROJECT RESULTS as follows: 

(a)    for non-commercial research purposes only and to grant sublicences to THIRD
PARTY academic institutions and not-for-profit research institutes for this purpose, whereby (i) these THIRD PARTIES shall be obliged to maintain confidentiality in
an appropriate form, and (ii) TRON or its respective 

  

			
	Strictly confidential	 	16

 
AFFILIATE shall grant, and hereby grants, the respective BIONTECH PARTY a non-exclusive, sublicensable, royalty-free, perpetual de-blocking license to any industrial property rights, know-how, technologies and other knowledge generated from any such
non-commercial research conducted with the WP5 RESULTS during a period ending on the 8th (eighth) anniversary of the completion of the generation of the
relevant WP5 RESULT, as necessary for the exploitation of the rights granted to it pursuant to Section 5.1 and shall ensure that it receives, under a written agreement with each such THIRD PARTY academic institutions or not-for-profit research institute, sufficient license or ownership rights to any and all industrial property rights, know-how,
technologies and other knowledge generated from any such non-commercial research conducted with the WP5 RESULTS in order to be able to grant the foregoing non-exclusive
license; and 
 (b)    for research, development and performance of diagnostic services, including the right to
sublicense to AFFILIATES, to the extent that these diagnostic services are provided solely to direct patient customers and medical health care centers solely for clinical care of patients, but not to any other entities, including drug manufacturers
or manufacturers of medical devices and research-based pharmaceutical companies. 
  

	5.6	 As between the PARTIES, ownership and rights of use with respect to
PRE-EXISTING KNOWLEDGE shall remain exclusively with TRON. However, if the PRE-EXISTING KNOWLEDGE of TRON is required for the respective BIONTECH PARTY for the use of
the WP5 RESULTS and/or the RNT PROJECT RESULTS according to clauses 5.1 and 5.2 (and possibly documented under clause 4.4), TRON shall grant the relevant company of the BIONTECH GROUP an irrevocable, sublicensable,
non-exclusive licence for use for the purposes of the respective WP5 PROJECT or exploitation of the relevant WP5 RESULTS and/or RNT PROJECT RESULTS. Compensation for that licence shall be covered by the
payments pursuant to clause 6.4. For clarification: the licences according to the LICENCE AGREEMENT remain unaffected by this. 

  

	6.	 Financial terms, terms of payment 

 

	6.1	 In the case of WP5 PROJECTS, the annual budget “ANNUAL BUDGET” for

  

			
	Strictly confidential	 	17

	 	
performing the WP5 PROJECT WORK shall be bindingly agreed between TRON and BIONTECH at the latest by [***] in each respective calendar year. The timing and mechanism of sharing of each of the WP5
PROJECT budgets that altogether make up the ANNUAL BUDGET will be subject to mutual agreement between TRON’s Managing Director and BIONTECH’s Chief Financial Officer. Whereas each WP5 PROJECT actuals can increase or decrease versus their
respective budgets over the financial year, the ANNUAL BUDGET cannot be exceeded without mutual agreement between TRON’s Managing Director and BIONTECH’s Chief Financial Officer. Unless otherwise agreed, TRON shall invoice WP5 PROJECT WORK
in accordance with clause 6.2. 

  

	6.2	 Unless otherwise agreed, the WP5 PROJECT WORK shall be invoiced for each month in arrears.

 Costs for material, insofar as they can be allocated to a WP5 PROJECT, are shown and invoiced separately on the invoice
in the form of direct costs of material and research services. 
 Costs for the keeping of animals and the use of Next Generation Sequencing
Machines (NGS) will, as far as possible, also be shown separately on the invoice and charged. 
  

	6.3	 TRON shall provide the BIONTECH PARTY with the invoice for WP5 PROJECT WORK for each month by the end of the
[***] calendar day of the following month. The remuneration shall be paid monthly at the latest on the [***] calendar day after receipt of invoice by payment to the bank account specified by TRON. 

 

	6.4	 In return for the granting of rights to TRON’s interest in the WP5 RESULTS and the RNT PROJECT RESULTS
pursuant to clause 5, the BIONTECH PARTY shall make the following payments: 

  

	6.4.1	 For the WP5 CONTRACTUAL PRODUCTS sold by it or its licensees (or sublicensees) to THIRD PARTIES which fall
within the scope of protection of a VALID CLAIM of a WP5 PROJECT PATENT or a TRADE SECRET INVENTION, the BIONTECH PARTY shall pay TRON remuneration to the amount of 

  

			
	Strictly confidential	 	18

	 	(i)	 [***] percent ([***]%) of the WP5 CONTRACTUAL PRODUCT’s NET SELLING PRICE up to an annual aggregate
worldwide NET SELLING PRICE per WP5 CONTRACTUAL PRODUCT of [***] ([***]); and 

  

	 	(ii)	 [***] percent ([***]%) of the WP5 CONTRACTUAL PRODUCT’s NET SELLING PRICE if the annual aggregate
worldwide NET SELLING PRICE per WP5 CONTRACTUAL PRODUCT exceeds [***] ([***]). 

 The aforementioned remuneration under
this clause 6.4.1 shall be paid on a country-by-country basis for so long as the relevant WP5 CONTRACTUAL PRODUCT is covered by a VALID CLAIM of a WP5 PROJECT PATENT in
the country of sale. 
 If a WP5 CONTRACTUAL PRODUCT falls within the scope of a TRADE SECRET INVENTION, it is the mutual expectation
of the PARTIES that the exploitation of such TRADE SECRET INVENTION will be coherent and jointly together with the exploitation of one or more WP5 PROJECT PATENTS. Based on that understanding, the royalty pursuant to this clause 6.4.1 for the use of
a TRADE SECRET INVENTION shall only be payable (x) if the relevant WP5 CONTRACTUAL PRODUCT also falls within the scope of protection of a VALID CLAIM of a WP5 PROJECT PATENT or, (y) in the event that the BIONTECH PARTY should exploit a
TRADE SECRET INVENTION by entering into an agreement with a THIRD PARTY, if the relevant WP5 CONTRACTUAL PRODUCT also falls within the scope of protection of a VALID CLAIM of a patent (co)owned by such THIRD PARTY (“THIRD PARTY PATENT”).
If such exploitation is undertaken without necessarily exploiting one or more WP5 PROJECT PATENTS or THIRD PARTY PATENTS (as applicable), TRON and the BIONTECH PARTY shall in good faith discuss how to adequately handle such situation and mutually
agree on a fair solution, in particular relating to royalties and/or other fair financial compensation of TRON for the BIONTECH PARTY’s exploitation of the TRADE SECRET INVENTION. 

The royalty is payable, on a WP5 CONTRACTUAL PRODUCT-by- WP5 CONTRACTUAL PRODUCT basis, only once per
WP5 CONTRACTUAL PRODUCT, even if a WP5 CONTRACTUAL PRODUCT falls within the scope of protection of several WP5 PROJECT PATENTS and/or TRADE SECRET INVENTIONS. 

  

			
	Strictly confidential	 	19

	6.4.2	 In addition: 

  

	 	•	 	 the BIONTECH PARTY shall pay in case of licensing under a WP5 PROJECT PATENT or under a TRADE SECRET INVENTION to
THIRD PARTIES, a share of [***] percent ([***]%) in all upfront payments, milestone payments and other remunerations (except royalties, to which clause 6.4.1 applies) that the BIONTECH PARTY or its AFFILIATES receive from its sublicensees for the
granting of such licences. For the avoidance of doubt, such sublicense fees as stated above are only payable to the extent they are actually paid to the BIONTECH PARTY for licenses granted. No share shall be payable on any remuneration that is
demonstrably paid for the provision of services, for the supply of materials, etc. In the case of a remuneration package, it may be necessary to determine the share paid for the licenses, and license fees shall only be paid on such share. Further,
the payment obligation shall not apply if the WP5-PROJECT PATENT or the TRADE SECRET INVENTION is sold to a THIRD PARTY in the context of a sale of all assets belonging to the respective business unit (asset
deal); however, the payment obligation shall also apply in the event of such a sale insofar as the respective transaction is economically equivalent to a licence agreement as typically concluded between biotechnology/pharmaceutical companies where
the licensee has to pay an upfront payment, milestone payments and sales-related payments (royalties); and 

  

	 	•	 	 BIONTECH shall pay, in the event that the aggregate of all NET SALES of a particular WP5 CONTRACTUAL
PRODUCT made by any BIONTECH PARTY or its sublicensees in a given CALENDAR YEAR exceed [***] ([***]), a sales milestone payment of [***] ([***]). The foregoing milestone payment shall be payable only upon the first achievement of such milestone, and
no amounts shall be due for subsequent or repeated achievements of such milestone in the same or subsequent CALENDAR YEARS, either with the same WP5 CONTRACTUAL PRODUCT or any other WP5 CONTRACTUAL PRODUCT; and 

 

	 	•	 	 Subject to Clause 2.3 and Clause 2.4 as applicable, the PARTIES shall

  

			
	Strictly confidential	 	20

	 	 
negotiate in good faith a non-refundable upfront payment based upon the contributions of TRON of said project. If the PARTIES do not reach agreement upon
the size of the upfront payment for the licensing of such a project, the upfront payment will be proposed by an independent expert familiar with collaboration and licensing transactions in the area of the research, development and commercialization
of the RNT PROJECT or projects under Clause 2.3 respectively based on lege artis market analytics and financial valuation methods (i.e. discounted cash flow), taking into account the other payments for the grant of the license to the RNT
PROJECT RESULTS or projects under Clause 2.3 respectively due to TRON pursuant to this section 6.4, additional intellectual property needed to commercialize and the stage of development of the project at the time of the contemplated license grant by
TRON to BIONTECH. In the case that the PARTIES have not reached agreement on the size of the upfront payment for the licensing of the RNT PROJECT a proposal by an independent expert is requested. Such independent expert must be reasonably acceptable
to TRON and BIONTECH and will be agreed upon and jointly appointed by TRON and BIONTECH within [***] days following execution of this WP5 AGREEMENT, and the determination shall be delivered within [***] months following the appointment of the
independent expert. 

  

	6.5	 If a company of the BIONTECH GROUP has, for the sale of a WP5 CONTRACTUAL PRODUCT, to pay a royalty under the
LICENCE AGREEMENT and/or the WP3 AGREEMENT, the royalty payable under the LICENCE AGREEMENT and/or the WP3 AGREEMENT for this WP5 CONTRACTUAL PRODUCT subject to payment shall be offset against the fee pursuant to clause 6.4.1 of this WP5 AGREEMENT.
If, under the LICENCE AGREEMENT, TRON receives a one-off and/or milestone payment (upfront or milestone payment) for the use or granting of usage rights to a WP5 CONTRACTUAL PRODUCT under the LICENCE
AGREEMENT, such a payment shall be set off against any payment due under clause 6.4.2. 

  

	6.6	 The BIONTECH GROUP company shall notify TRON of the fees payable to TRON by a BIONTECH GROUP company pursuant
to clause 6.4 for each calendar quarter, including the basis of calculation (NET SELLING PRICES and royalty payments by licensees or sublicensees pursuant to clause 6.4) within [***] month after the end of the previous calendar quarter. The
corresponding payment to TRON shall be due within a further month, but no later than [***] months after the end of the previous calendar quarter. 

  

			
	Strictly confidential	 	21

	6.7	 All payments must be made in Euro plus any applicable value-added tax. If NET SELLING PRICES are collected in
foreign currencies, they shall be converted at the exchange rate published by the European Central Bank at 3 p.m. on the last business day of the relevant accounting period. Each payment shall be due within [***] working days of the end of the
calendar quarter to which the payment relates. 

  

	6.8	 Each company of the BIONTECH GROUP shall keep all books, records and other data which are necessary to
determine the accuracy and completeness of the notifications and accounts pursuant to clauses 6.6 and 6.7, in accordance with generally accepted accounting principles. TRON shall be entitled, after reasonable notice, to have them audited by an
independent accounting firm reasonably acceptable to BIONTECH (acting reasonably), once a year during normal business hours. TRON shall assume the costs of such audit unless the audit shows that there is a difference to TRON’s disadvantage of
[***] percent ([***]%) or more between the calculation of the respective BIONTECH PARTY and the calculation found to be correct by the auditor, in which case, the costs of the audit shall be borne by the BIONTECH PARTY. Differences shall become due
and payable with immediate effect. 

  

	7.	 Warranty, liability 

 

	7.1	 Each PARTY hereby warrants that it is entitled to conclude this WP5 AGREEMENT and perform its obligations under
this WP5 AGREEMENT and that it is not aware of any circumstances that could impair one of the PARTIES in the performance of its obligations under this WP5 AGREEMENT. For the avoidance of doubt: TRON hereby also warrants that it is entitled to grant
licenses for the WP5 RESULTS and the RNT PROJECT RESULTS. 

  

	7.2	 TRON undertakes that TRON shall not enter into any agreements with THIRD PARTIES that restrict it in relation
to the respective WP5 PROJECT WORK to be provided. 

  

	7.3	 The PARTIES shall inform each other of THIRD PARTY industrial property rights and copyrights which they know or
become aware of and which could be 

  

			
	Strictly confidential	 	22

	 	
infringed by the use of the WP5 RESULTS and/or the RNT PROJECT RESULTS. They shall decide by mutual agreement whether and how THIRD PARTIES rights that become known are to be taken into account
in the context of WP5 PROJECTS. 

  

	7.4	 If a claim is asserted against a PARTY due to the contractual use of results generated on the basis of this WP5
AGREEMENT or due to the infringement of THIRD PARTY industrial property rights, the respective PARTY shall inform the other PARTY concerned thereof without delay. If the charged PARTY defends itself against the allegations of injury, the other PARTY
shall reasonably support the charged PARTY. 

  

	7.5	 The respective companies of the BIONTECH GROUP and TRON shall only be liable to each other for wilful
misconduct and gross negligence. In the event of gross negligence, liability for indirect damage, consequential damage and loss of profit shall be excluded. 

  

	7.6	 The BIONTECH PARTIES shall indemnify TRON against any THIRD PARTY CLAIMS for product liability in connection
with WP5 CONTRACTUAL PRODUCTS and against all THIRD PARTY CLAIMS asserted against TRON alleging the exploitation of WP5 RESULTS and/or RNT PROJECT RESULTS by any BIONTECH PARTY, its AFFILIATES, licensees (and sublicensees) and distributors infringes
the intellectual property rights of THIRD PARTIES. However, the BIONTECH PARTY shall only be obliged to indemnify TRON under the following conditions: (i) TRON promptly notifies the BIONTECH PARTY in writing of any such claim; (ii) the
BIONTECH PARTY is solely entitled to defend and settle the claim; and (iii) TRON assists the BIONTECH PARTY in defending the claim to the best of its ability and against reimbursement of reasonable expenses incurred in defending the claim.

  

	8.	 Confidentiality, publications 

 

	8.1	 The PARTIES undertake to keep confidential any CONFIDENTIAL INFORMATION received directly or indirectly from
any of the other PARTIES, not to make this information available to THIRD PARTIES (subject to clause 8.3) and to use it only for the purposes of the WP5 PROJECTS. 

  

			
	Strictly confidential	 	23

	8.2	 The foregoing obligations shall not apply to such CONFIDENTIAL INFORMATION from which the PARTY receiving the
information can demonstrate that it: 

  

	 	(i)	 was already generally accessible at the time of its disclosure (or, as relating to WP5 RESULTS, at the time of
its generation by TRON) or subsequently became generally accessible through no fault of the receiving PARTY, 

  

	 	(ii)	 was already in the receiving PARTY’s possession at the time of disclosure (or, as relating to WP5 RESULTS,
at the time of its generation by TRON), 

  

	 	(iii)	 had been made available to the receiving PARTY by a THIRD PARTY without any obligation of confidentiality or non-use, or 

  

	 	(iv)	 to the extent it must be disclosed pursuant to a binding order of a competent court or authority due to legal
regulations. 

 For the avoidance of doubt Clauses 8.2 (i) and (ii) shall not operate to exclude the WP5 RESULTS and
the RNT PROJECT RESULTS from the Confidential Information of the BIONTECH PARTIES. 
  

	8.3	 The PARTIES undertake to make the CONFIDENTIAL INFORMATION available only to such employees, agents and THIRD
PARTIES who, for the purposes of the relevant WP5 PROJECT, have a need to know the information, or to THIRD PARTIES who have a good faith interest in the acquisition of all or substantially all of the assets of the relevant branch of business of a
PARTY, and to whom the same confidentiality obligations as entered into by the PARTIES were imposed also for the period after the termination of the employment, service or other relationship. Upon termination of the WP5 AGREEMENT, the receiving
PARTY shall return all CONFIDENTIAL INFORMATION and copies thereof to the disclosing PARTY or, at the disclosing PARTY’s option, destroy them. 

  

	8.4	 Neither PARTY shall make any publication during the term of this WP5 AGREEMENT and until [***] years after its
termination, in so far as the interests of the other PARTIES may reasonably be affected, in particular if the planned publication contains WP5 RESULTS, without the consent of the PARTY concerned. The other PARTY shall be obliged to give its consent
or to 

  

			
	Strictly confidential	 	24

	 	
object within [***] weeks after receipt of the complete manuscript of the planned publication. If the PARTY does not object to publication within this period, consent shall be deemed granted.
Publication may only be objected to for good cause. A good cause is in particular if (i) a PARTY intends to file patent applications for inventive contributions contained in the publication in good time, in which case [***] months after
delivery of the complete manuscript of the planned publication and knowledge of the PARTIES of the WP5 RESULT eligible for patent protection are agreed as the maximum period by which a publication may be delayed for the purpose of the patent
application, or (ii) the PARTIES have mutually determined not to file patent application but instead maintain an invention as a TRADE SECRET INVENTION, in which case the TRADE SECRET INVENTION and any data relating to it would not be published.
However, in the event of an objection being raised against a publication, the PARTIES, especially insofar as final examinations, doctoral or postdoctoral theses are affected by the work in the project, shall endeavour in any case to jointly find a
compromise in terms of time and/or content for early publication, taking into account the legal obligations and legitimate interests of their examinees, doctoral candidates or postdoctoral candidates concerned. 

 

	8.5	 The confidentiality obligation shall continue for [***] years after termination of this WP5 AGREEMENT.

  

	9.	 Term, termination 

 

	9.1	 This WP5 AGREEMENT shall enter into force as of the EFFECTIVE DATE and shall run for an indefinite period. It
may be terminated by either PARTY with [***] months’ prior written notice. 

  

	9.2	 Each individual WP5 PROJECT AGREEMENT shall commence on the date of its execution and shall terminate on the
completion of the WP5 PROJECT WORK. The PARTIES may, subject to the following provisions of this clause 9, terminate individual WP5 PROJECT AGREEMENTS without affecting other existing WP5 PROJECT AGREEMENTS or may terminate all existing WP5 PROJECT
AGREEMENTS. WP5 PROJECT AGREEMENTS, which have been signed at the time of a termination of this WP5 AGREEMENT as a whole pursuant to clause 9.1 shall remain unaffected by such termination and shall be continued in accordance with the provisions of
this WP5 

  

			
	Strictly confidential	 	25

	 	
AGREEMENT until completion of the relevant WP5 PROJECT WORK. Unless otherwise agreed in a WP5 PROJECT AGREEMENT, a WP5 PROJECT AGREEMENT may be terminated by BIONTECH at the end of the calendar
month with [***] months’ notice. 

  

	9.3	 The PARTIES’ right to terminate the contract for good cause shall remain unaffected.

  

	9.4	 Any termination must be in writing. 

 

	9.5	 If a BIONTECH GROUP company terminates the WP5 AGREEMENT, the WP5 AGREEMENT between the remaining BIONTECH
GROUP companies and TRON shall otherwise remain unchanged. 

  

	9.6	 Clauses 5.1, 5.2, 5.3, 5.5, 5.6, 6, 7, 8, 9.6 and 10 shall continue to apply after termination of this WP5
AGREEMENT. 

  

	10.	 Final provisions 

 

	10.1	 The provisions of the LICENCE AGREEMENT shall not be affected by the provisions of this WP5 AGREEMENT and shall
prevail over the provisions of this WP5 AGREEMENT in the event of any contradictions. 

  

	10.2	 The PARTIES shall be entitled to transfer their rights and obligations under this WP5 AGREEMENT to their
AFFILIATES; they shall also be entitled to transfer such rights and obligations to THIRD PARTIES together with all or substantially all of its business assets to which this WP5 AGREEMENT pertains. The PARTIES shall immediately notify each other of
the above-mentioned transfers in writing in order to minimise any negative effects for the other PARTY, and, between the relevant PARTIES, any such permitted assignment will not enter into effect until the respective other PARTY’s receipt of
such notice. 

  

	10.3	 All notices from TRON to BIONTECH or from BIONTECH to TRON regarding this WP5 AGREEMENT shall be sent by post
or by fax and confirmation copy by post to the following addresses of TRON and BIONTECH: 

 To TRON: 

TRON-Translationale Onkologie 

  

			
	Strictly confidential	 	26

 an der Universitätsmedizin 

der Johannes Gutenberg – Universität Mainz gemeinnützige GmbH 

[***] 
 Freiligrathstraße 12

 D-55131 Mainz, Germany 

To BIONTECH: 
 BioNTech AG 

An der Goldgrube 12 
 D-55131 Mainz, Germany 
 F.A.O [***] 

 

	10.4	 To the extent that TRON has obligations to one or more companies of the BIONTECH GROUP under this WP5 AGREEMENT
or otherwise in connection with a WP5 PROJECT, BIONTECH shall be entitled and obliged to receive the relevant service from TRON with effect of fulfilment (Erfüllungswirkung) for and against all companies of the BIONTECH GROUP affected.

  

	10.5	 This WP5 AGREEMENT is subject to the laws of Germany with the exception of the German conflicts of law
provisions and without regard to the UN Convention on Contracts for the International Sale of Goods. 

  

	10.6	 With regard to all disputes arising from or in connection with this WP5 AGREEMENT, mediation shall be conducted
in accordance with the Conciliation Rules of the German Institution of Arbitration (Deutsche Institution für Schiedsgerichtsbarkeit e.V. – DIS) as amended at the initiation of the proceedings. The place of mediation shall be Frankfurt am
Main, Germany. The number of mediators is one (1). The language of the mediation procedure is German. If the dispute is not settled under the rules of conciliation within [***] days after a request for mediation or within any other period agreed in
writing by the PARTIES, each PARTY shall be entitled to resolve the dispute in accordance with clause 10.7. 

  

	10.7	 After unsuccessful execution of the mediation procedure pursuant to clause 10.6, all disputes arising from or
in connection with this WP5 AGREEEMENT or concerning its validity shall be settled in accordance with the arbitration rules of 

  

			
	Strictly confidential	 	27

	 	
the DIS to the exclusion of the due process of law. The place of arbitration shall be Frankfurt am Main, Germany. The number of arbitrators shall be three (3). The language of the arbitration
proceedings shall be German. 

  

	10.8	 Should individual provisions of this WP5 AGREEMENT be or become invalid or unenforceable, this shall not affect
the validity of the remaining provisions. The PARTIES undertake without undue delay to replace an invalid or unenforceable provision by a valid or enforceable provision that comes as close as possible to the economic effect of the provision to be
replaced. 

  

	10.9	 In the event of any conflict between the WP5 PROJECTS and this WP5 AGREEMENT, this WP5 AGREEMENT shall prevail
over the conflicting provisions of the WP5 PROJECT, unless the priority of the provisions of the WP5 PROJECT is expressly agreed between the relevant PARTIES of the WP5 PROJECT in the relevant WP5 PROJECT AGREEMENT. 

 

	10.10	 Any amendments and changes to this WP5 AGREEMENT must be made in writing in the form of a document signed by
the PARTIES. This also applies to the waiver of the written form requirement. 

 – Signature page follows –

  

			
	Strictly confidential	 	28

			
		
	 Place, date:
	 	  

		
	 BioNTech SE
	 	
		
	 Signed by: [***]
	 	  

		
	 Name: [***]
	 	  

		
	 Title: [***]
	 	  

 BioNTech RNA Pharmaceuticals GmbH 
  

			
	 Signed by: [***]
	 	  

		
	 Name: [***]
	 	  

		
	 Title: [***]
	 	  

 BioNTech Diagnostics GmbH 
  

			
	 Signed by: [***]
	 	  

		
	 Name: [***]
	 	  

		
	 Title: [***]
	 	  

  

			
	Strictly confidential	 	29

 JPT Peptide Technologies GmbH 
  

			
	 Signed by: [***]
	 	  

		
	 Name: [***]
	 	  

		
	 Title: [***]
	 	  

 TRON-Translationale Onkologie 

at the Universitätsmedizin der Johannes Gutenberg – Universität Mainz gemeinnützige GmbH 

 

							
	Signed by: [***]                                 
	 		  	Signed by: [***]                         	 	
				
	Name: [***]                                   
    	 	                	  	Name: [***]                                	 	
				
	Title: [***]                                 	 		  	Title: [***]                                  
	 	

  

			
	Strictly confidential	 	30

 Annex 1: 

List of WP5 PROJECTS covered by this WP5 AGREEMENT according to clause 2.2 

Annex 1A – FIELD I WP5 PROJECTS 
  

											
	 Project Name
	  	Project No.
Controlling	  	BNT Ref	  	 Project Description
	  	Field of
Use*	  	Status
09.07.2019
	 [***]
	  	[***]	  	[***]	  	 [***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	 [***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	•[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	 [***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	•[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	 [***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	 [***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	 [***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	•[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	•[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	 [***]	  	[***]	  	[***]

  

			
	Strictly confidential	 	31

 Annex 1B – FIELD II WP5 PROJECTS 

 

											
	 Project Name
	  	Project No.
Controlling	  	BNT Ref	  	 Project Description
	  	Field of
Use*	  	Status
09.07.2019
	 [***]
	  	[***]	  	[***]	  	•[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	•[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	•[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	•[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	•[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	•[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	•[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	•[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	 [***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	•[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	•[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	•[***]	  	[***]	  	[***]

  

			
	Strictly confidential	 	32

											
	 Project Name
	  	Project No.
Controlling	  	BNT Ref	  	 Project Description
	  	Field of
Use*	  	Status
09.07.2019
	 [***]
	  	[***]	  	[***]	  	•[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	•[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	•[***]	  	[***]	  	[***]

  

			
	Strictly confidential	 	33

 Annex 2: 

Template –WP5 PROJECT AGREEMENT 

WP5 PROJECT AGREEMENT 

PROJECT TITLE: 
 [Please
insert Project title, BIONTECH and TRON Project ID] 
 (ACRONYM) 

between 
 TRON
Translational Oncology at the University Medical Centre of Johannes Gutenberg – University of Mainz, a non-profit-making company, Freiligrathstraße 12,
D-55131 Mainz, Germany 
 (hereinafter referred to as “TRON”) 

xxx 
 (hereinafter referred
to as “BIONTECH”) 
 (TRON and BIONTECH hereinafter jointly referred to as the “Parties”) 

  

			
	Strictly confidential	 	34

 PREAMBLE 

This individual agreement on a WP5 PROJECT (“Individual project”) is concluded between the parties on the basis of the “Framework Cooperation
Agreement” between TRON and the companies of the BIONTECH GROUP (hereinafter referred to as the “WP5 AGREEMENT”). 
  

	1	 Objectives and contents of the WP5 PROJECT 

1.1 Short abstract 
 [Brief description of the
background of the project (max. 300 characters incl. spaces)] 
 1.2 Objectives and FIELD 

[Description of the WP5 project goals and the expected results and if applicable, the prerequisites for the execution of
the project. The field of use to which the results of the activities under this WP5 PROJECT will be granted (“Field” as defined under “1. Definitions” in the WP5 AGREEMENT)]. 

1.3 Work plan and time lines 
 The WP5 PROJECT WORK
comprise the following activities in detail: 
 [Overview of work packages, if necessary, interactions between work
packages, if available work package flowchart (UML). Description of the individual work packages including responsibilities and the planned deliverables for each work package]

  

													
	     #    
	  	Description	 	  	Start – End	 	  	Deliverables	 
	 WP1
	  	 	SHORT TITLE	 	  	 	QX20XX-QX20XX	 	  	 	XXX	 
	 WP2
	  	 	SHORT TITLE	 	  	 	QX20XX-QX20XX	 	  	 	XXX	 

 WPI TITLE 

[Description of the scientific rationale including the departments/persons involved, specification of the expected results including the technologies and
methods required for this; if required, detailed structuring of the work packages into sub-work packages; definition of milestones and deliverables for each work package; definition of termination criteria if
required] (max. 300 characters incl. spaces) 

  

			
	Strictly confidential	 	35

 WP2 TITLE 

[Description of the scientific rationale including the departments/persons involved, specification of the expected results including the technologies and
methods required for this; if required, detailed structuring of the work packages into sub-work packages; definition of milestones and deliverables for each work package; definition of termination criteria if
required] (max. 300 characters incl. spaces) 
 2 Scope of the PROJECT SERVICES and budget 

 

					
	 #
	  	 Estimated effort
	  	 Remuneration

	 WP1
	  	[Short description of WP1 activities (staining, sequencing etc.]	  	according to actual expenses
	 WP2
	  	[Short description of WP1 activities (staining, sequencing etc.]	  	according to actual expenses

 2.1 The remuneration to be paid to TRON for the WP5 PROJECT WORK in accordance with clause 6.1 of the WP5 AGREEMENT shall be
based on the actual expenses incurred by TRON. 
 2.2 Invoicing for all WP5 PROJECT WORK shall be carried out in accordance with clause 6.2 of the WP5
AGREEMENT. 
  

	3	 Materials for carrying out the PROJECT SERVICES 

3.1 BIONTECH shall provide TRON (if applicable through THIRD PARTIES) with the following materials free of charge for the performance of the WP5 PROJECT WORK:

  

					
	 Materials
	  	 Intended use
	  	 Quantity

	
                 
                           
	  	                                   
 	  	                                   
             
		  		  	
		  		  	
		  		  	
		  		  	

  

	4	 Project assignment and contact persons 

  

			
	Strictly confidential	 	36

			
		 	Project number/cost centre
	BIONTECH project number:        	 	
	TRON project number:	 	

 The parties shall appoint the following contact persons for the WP5 PROJECT: 

 

	
	 BIONTECH project management:

	Name:
	Position:
	Email:
	 BIONTECH project management:

	Name:
	Position:
	Email:
	
	 TRON project management:

	Name:
	Position:
	Email:

 The parties shall inform each other in good time in writing about any changes to the project number/cost centre or the contact
person. 
  

	5	 Documentation and data transfer 

TRON documents all WP5-PROJECT-related work according to internal documentation standards (order forms, handover
protocols, laboratory books). Data is stored in a WP5 PROJECT folder on the shared cooperation drive (TRON’s K-drive or BioNTech sharepoint) with defined access rules. 

[If necessary, make a note of additional documentation here. In particular, please detail here if you anticipate that an R&D study report for
regulatory purposes may be required. If that may be the case, please specify here whether such report shall follow TRON R&D Reporting SOP. Please outline responsible person for such report. A tabular format may be chosen.] 

 

	6	 Term 

This individual order shall become effective upon signature of both parties with an effective date of xx.xx.xx.xxxx. 

  

			
	Strictly confidential	 	37

	7	 Final clauses 

Unless expressly agreed otherwise in this individual order between the parties, all provisions of the WP5 AGREEMENT shall apply to this individual order
without restriction. 
 BIONTECH 
 Mainz, Germany,
                                 

 
 
                                         
                                         
                                       

Name: 
 Title: CFO 

TRON 
 Mainz, Germany,
                                 Mainz, Germany,
                               

 
 
                                         
                                         
                                       

Name:    Name: 

Title:    CEO Title:CEO 

  

			
	Strictly confidential	 	38

 This annex is an English translation of a document prepared in German. In preparing this
document, an attempt has been made to translate as literally as possible without jeopardizing the overall continuity of the text. Inevitably, however, differences may occur in translation and if they do, the German text will govern by law. 

In this translation, German legal concepts are expressed in English terms and not in their original German terms. The concepts concerned may
not be identical to concepts described by the English terms as such terms may be understood under the laws of other jurisdictions. 
 Annex 3

 TEMPLATE of a declaration for persons involved in WP5 PROJECTS who are not employed by TRON or a subcontractor involved in the relevant WP5
PROJECT (e.g. undergraduates, doctoral candidates, students) 
 During my work for the <Institution> when working on a project that will be
carried out under the “Framework Cooperation Agreement” between TRON and the companies of the BIONTECH GROUP (“WP5 AGREEMENT”), I hereby commit: 
  

	 	(i)	 to observing the attached confidentiality obligation (excerpt from the WP5 AGREEMENT) which is known to me and
which I have referred to in this statement as annex, which is primarily incumbent upon TRON with regard to the relevant companies of the BIONTECH GROUP within the context of the above-mentioned research services; and 

 

	 	(ii)	 to waiving the assertion of any negative right of publication under Article 42 no. 2 of the German Employee
Inventions Act with regard to all results achieved by me in connection with the above-mentioned project, provided that the German Employee Inventions Act and this Article are applicable to me; and 

 

	 	(iii)	 to reporting to TRON all inventions arising within the context of my participation in the project and to
transfer all results generated by me within the context of my participation in the project and all rights thereto to TRON; I hereby transfer all results generated by me within the context of my participation in the project and all rights thereto to
TRON. If a transfer cannot yet take place for legal reasons, I hereby undertake to make the necessary declarations to TRON for the transfer after the generation of the results. 

Name: 
 First name: 

Signature: 
 Acceptance by TRON: 

Name: 
 First name: 

Signature: 

  

			
	Strictly confidential	 	39

 Annex 4 

List of Patent Applications (as of the date of execution of this WP5 AGREEMENT) which covers WP5 PROJECTS covered by this WP5 AGREEMENT 

 

									
	 BNT
file no.
	  	Applicant	 	Title	 	Priority Date	 	Ref. no. - 1st app. or
app. claiming priority
(Publication no.)
	[***]	  	[***]	 	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]	 	[***]

  

			
	Strictly confidential	 	40

									
	 BNT
file no.
	  	Applicant	 	Title	 	Priority Date	 	Ref. no. - 1st app. or
app. claiming priority
(Publication no.)
	[***]	  	[***]	 	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]	 	[***]

  

			
	Strictly confidential	 	41

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]